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Abstract——Antiepileptic drugs (AEDs) have many
benefits but also many side effects, including aggres-
sion, agitation, and irritability, in some patients with
epilepsy. This article offers a comprehensive summary
of current understanding of aggressive behaviors in
patients with epilepsy, including an evidence-based
review of aggression during AED treatment. Aggression
is seen in a minority of people with epilepsy. It is rarely
seizure related but is interictal, sometimes occurring as
part of complexpsychiatric andbehavioral comorbidities,
and it is sometimes associated with AED treatment.
We review the common neurotransmitter systems
and brain regions implicated in both epilepsy and
aggression, including the GABA, glutamate, serotonin,
dopamine, and noradrenaline systems and the
hippocampus, amygdala, prefrontal cortex, anterior
cingulate cortex, and temporal lobes. Few controlled
clinical studies have used behavioral measures to
specifically examine aggression with AEDs, and most
evidence comes from adverse event reporting from
clinical and observational studies. A systematic approach
was used to identify relevant publications, andwepresent
a comprehensive, evidence-based summary of available
data surrounding aggression-related behaviors with each
of the currently available AEDs in both adults and in
children/adolescents with epilepsy. A psychiatric history
and history of a propensity toward aggression/anger
should routinely be sought from patients, family
members, and carers; its presence does not preclude
the use of any specific AEDs, but thosemost likely to be
implicated in these behaviors should be used with
caution in such cases.
I. Introduction
The past 20 years have seen the introduction of .15
antiepileptic drugs (AEDs), many with unique mecha-
nisms of action (Löscher et al., 2013). Nevertheless,
.30% of adolescent and adult patientswith the common
epilepsies continue to have seizures, despite receiving
treatment withmany of these drugs used either singly or
in combination (Brodie et al., 2012). Outcomes in child-
hood epilepsies, excluding the genetic encephalopathies
of infancy, are equally disappointing (Geerts et al., 2010).
In parallel with these pharmacological developments has
come an increasing awareness that people with epilepsy,
possibly as many as 30% of the newly diagnosed popula-
tion and up to 50% of patients with pharmacoresistant
epilepsy, have complex psychiatric, behavioral, cogni-
tive, and social problems (Lin et al., 2012). Indeed, these
problems often precede the onset of epilepsy (Hesdorffer
et al., 2012). The presence of psychiatric comorbidities
contributes to the likelihood that seizures will prove
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resistant to both AEDs and epilepsy surgery (Hitiris
et al., 2007; Kanner et al., 2009; Petrovski et al., 2010).
The situation is further complicated by the beneficial
psychotropic effects of some AEDs and the adverse
properties of others (Piedad et al., 2012). Behavioral
side effects that have been associated with AEDs
include depression, aberrant behaviors, and the devel-
opment or worsening of irritability, impulsivity, anger,
hostility, and aggression. Although prior reviews have
focused on the associations between AEDs and depres-
sion or aberrant behaviors, the specific topic of aggression
in response to AEDs has been largely neglected. We have
endeavored in this evidence-based review to explore the
neurobiology, epidemiology, presentation, clinical rele-
vance, and management of issues relating to aggression
in children, adolescents, and adultswith newly diagnosed
and chronic epilepsy exposed to a range of established
and modern AEDs.
II. Aggressive Behavior in Epilepsy: Definitions
Aggressive behavior in epilepsy has been the subject
of many misconceptions and controversies (Schachter,
2007). In the context of seizures, aggressive behaviors
have been observed in the preictal, ictal, and postictal
states (before, during, and after the seizure, respectively),
although directed and purposeful ictal aggression has
only rarely been observed (Delgado-Escueta et al., 1981).
Interictal aggressive behaviors (during periods between
seizures) have sometimes been attributed to the irrita-
bility described in what some have termed an “interictal
dysphoric disorder” of epilepsy (Blumer, 1997).
Medications, including some AEDs, have been asso-
ciated with the induction or exacerbation of adverse
psychotropic effects, including aggression (Ettinger,
2006). Our knowledge of aggression and related effects
such as irritability is based on reviews of predominantly
spontaneous reporting of psychiatric symptoms in
clinical case experience or in premarketing drug trials.
One challenge in determining the rate and nature of
AED-induced aggression is the fact that most studies
are focused on the antiseizure efficacy of AEDs, as well
as on the capture of more traditional potential ad-
verse events (AEs) such as fatigue or rash, and do not
rigorously assess psychiatric symptoms. Furthermore,
the terminology for aggression and related terms is not
well defined and is not universally accepted even among
experts in the field of psychiatry.
Some measures have been developed to detect or rate
aggression-related behaviors, but these are rarely used
in the context of premarketing trials of AEDs. Instead,
psychiatric symptoms are typically reported by patients
using informal terms that do not adhere to strict
diagnostic criteria. These informal terms are usu-
ally standardized and categorized using the Medical
Dictionary for Regulatory Activities (MedDRA), an
internationally endorsed dictionary and thesaurus
for medical terminology. For example, when a patient
reports “feeling queasy” and this is entered into the
study database, this is categorized into a more specific
“preferred term” (nausea) to which other related symp-
tom descriptors are also linked. Related preferred terms
are grouped into high-level terms (nausea and vomit-
ing), which are in turn grouped into high-level group
terms and ultimately system organ classes (gastroin-
testinal disorders). Standardized MedDRA queries
(SMQs) have been developed (and extensively reviewed
and tested) that can look across these groupings for terms
that are related to the condition of interest. SMQs can be
narrow (terms that are highly likely to represent the
condition of interest) and thus have high specificity but
low sensitivity; or they can be broad, with higher sensi-
tivity at the expense ofmore false positives (i.e., will select
some AEs that will, on inspection, not be related to the
event in question). Thus, the narrow SMQ for hostility/
aggression identifies AE terms that are very likely to be
related (e.g., “anger” and “physical assault”). The broad
SMQ also includes broadly related terms, such as “skin
laceration,” that will often not be related to hostility or
aggression but will be a direct result in some cases.
We considered agitation, anger, hostility, impulsivity,
and irritability as the most important terms that are
related to and encompass aggression and related behav-
iors.We therefore used these terms to direct our searches
for evidence of aggression associated with AEDs, and we
review the terms here in the way in which they are
traditionally used in the psychiatric literature. None of
these terms themselves are individual diagnoses in the
fifth edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM), but some (particularly irrita-
bility, impulsivity, and aggression) are used to describe
important components and symptoms of psychiatric
diagnoses (American Psychiatric Association, 2013).
A. Aggression
Even in the fields of psychology or psychiatry, terms
such as aggression, anger, hostility, or irritability have
been used loosely and interchangeably. Proposed defi-
nitions have gone through numerous iterations. Dollard
et al. (1939) defined aggression as “the affectively driven
attack on another with the intent to do harm.”Feshbach
(1964) proposed a distinction between anger-motivated
hostile aggression and instrumental aggression (in
which anger and intent to harm could be absent but
harm does result). DiGiuseppe and Tafrate (2007)
returned to the concept of intent to harm, defining
aggression as “overt motor behaviour enacted with the
intent to do harm or injury to a person or object, with the
expectation that harm will occur.” Associated affective
statesmay include irritation, frustration, fear, and even
pleasure (Campbell, 2009).
Aggression may appear as “hostile, threatening, and
violent behaviors” (Onyike and Lyketsos, 2011). It has
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also been noted that “behaviors range from assertiveness
to coercion (including the use of force) and from hostile
attitudes and verbal abuse to threats, belligerence, and
violence” (Campbell, 2009). There may be no, trivial, or
minimal provocation (Onyike and Lyketsos, 2011).
Aggression may be a symptom of diverse psychiatric
conditions, including “delusional psychoses, dementia,
agitated delirium, intoxication, conduct disorder in
children or personality disorders (particularly antisocial,
borderline, paranoid, and narcissistic types) in adults,
and even adjustment disorder” (Onyike and Lyketsos,
2011). Aggression may also complicate nonpsychiatric
illnesses because it can develop when patients feel
disregarded or “angered by perceived unfairness or mis-
treatment, or as a ‘primary’ symptom of the illness”
(Onyike and Lyketsos, 2011). Aggressive behaviors have
also been described as an adverse psychotropic effect of
medications such as AEDs (Dinkelacker et al., 2003).
Indeed, Gollan et al. (2005) distinguished medically
related aggression from premeditated or impulsive types.
From an evolutionary perspective, aggression may
have developed in humans for self-preservation (e.g.,
protecting offspring) but also for “retaliation, material
advantage, and power” (Onyike and Lyketsos, 2011). It
can serve as a behavior designed to attain a goal or
defend against threats (Miczek et al., 2002; Takahashi
et al., 2011). Aggression is amanifestation of “appetitive
drives” in some situations, whereas it is a defensive
behavior in others (Onyike and Lyketsos, 2011).
B. Agitation
Agitation is “a state of pathologically intense emo-
tional arousal and motor restlessness” (Onyike and
Lyketsos, 2011), typically associated with hyperactive
behaviors such as handwringing or aimlessly pacing
(Campbell, 2009) or “cursing, screaming, biting, and
fighting, and it may evolve through a verbally or
physically aggressive behavior” (Comai et al., 2012a,
b). It is characterized by “inappropriate verbal, vocal, or
motor activity that is not explained by apparent needs
or confusion per se” (Comai et al., 2012a).
C. Anger
Anger was defined by Spielberger (1996) as “an
emotional state, varying in intensity from mild annoy-
ance to rage, that is accompanied by arousal of the
autonomic nervous system.” Spielberger distinguished
the anger state (the experience of these emotions) from
trait (a tendency toward recurrently experiencing these
emotions). DiGiuseppe and Tafrate (2007) proposed a
more multidimensional construct defining anger as “a
constellation of specific uncomfortable subjective expe-
riences and associated cognitions (e.g., thoughts, be-
liefs, images) that have variously associated verbal,
facial, bodily, and automatic reactions.” They further
emphasize that anger is experienced in “people’s
conscious awareness and is communicated through
verbalizations and bodily reactions” (DiGiuseppe and
Tafrate, 2007).
D. Hostility
An older literature describes hostility in the context of
personality traits: “an attitude of resentment, suspi-
ciousness, and bitterness coupled with the desire to get
revenge or to have destructive goals for one’s anger”
(Endler and Hunt, 1968). Spielberger (1988) defined it
as “the disposition to perceive a wide range of situations
as annoying or frustrating, and the tendency to respond
to such situations with more frequent elevations in
state anger.” Both Spielberger (1988) and Barefoot
(1992) divide hostility into cognitive components (e.g.,
negative beliefs, cynicism, mistrust), an affective or
emotional component (i.e., varying degrees of anger),
and the behavioral component (verbal or physical
assault with intent to cause harm), whereas others
contend that the term “hostility” should be reserved for
the cognitive component (Vollrath, 2006).
E. Impulsivity
Impulsivity may be described as “acting without
control or premeditation” (Comai et al., 2012a) or
“behaving recklessly without regard to consequences”
(Hollander et al., 2000). In less formal terms, it may be
conceptualized as “acting without thinking” (Barratt,
2000) or without self-restraint, with a tendency toward
“hair-trigger” actions (Onyike and Lyketsos, 2011).
Campbell’s Psychiatric Dictionary defines impulsivity
as “a predisposition toward rapid, unplanned reactions
to internal or external stimuli with diminished regard
to the negative consequences of these reactions to the
impulsive individual or others.” Campbell (2009) fur-
ther notes it to be “a pattern of behavior consisting of
rapid, unplanned actions which occur unexpectedly,
without reflection or conscious judgment, and without
regard for possible consequences.”
F. Irritability
Irritability is a term that is commonly used in DSM-5
(American Psychiatric Association, 2013) as a compo-
nent of psychiatric diagnoses such as major depressive
disorder or generalized anxiety disorder (DiGiuseppe
and Tafrate, 2007), but the term itself is not defined
there. Irritability also accompanies many neurologic
disorders such as dementia and is a component of the
controversial interictal dysphoric disorder of epilepsy
(Blumer et al., 2004; Amiri and Hansen, 2015).
Work by Born and Steiner (1999), as summarized by
DiGiuseppe and Tafrate (2007), described five compo-
nents of irritability: “1) a heightened or excessive
sensitivity to external stimuli, 2) a negative affective
state, 3) a state of physical and psychological tension
that may suddenly and rapidly escalate, 4) reduced
control over temper, proneness to anger, annoyance, or
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impatience, and 5) irascible verbal behavior outbursts,
or even explosive behavior.”
Piazzini emphasized the extreme sensitivity to stim-
ulation of any kind and excessive response to “environ-
mental, situational and emotional stimuli” (Caprara
et al., 1992; Piazzini et al., 2011). Coccaro et al. (1991,
2000) define irritability succinctly as “a tendency to
respond with negative affect in reaction to aversive
stimuli or with hypersensitivity to aversive stimuli.”
To summarize, although there are diverse terms that
relate to the concept of aggressive behaviors, this review
uses the phrases “aggression” and “aggressive behaviors”
to express the broad range of associated concepts including
agitation, anger, hostility, impulsivity, and irritability.
III. Aggressive Behavior in Epilepsy:
Clinical Aspects
There is clear evidence that psychiatric disorders are
more frequently encountered in patients with epilepsy
than in the general population, with prevalence rates in
the range of 20%–30% for mood and anxiety disorders
and 2%–7% for psychoses (Lin et al., 2012).
In general terms, the wide range of manifestations of
aggression described earlier have been reported by many
different authors in people with epilepsy (Bach-y-Rita
et al., 1971; Maletzky, 1973; Maletzky and Klotter, 1974;
Ratner and Shapiro, 1979; Leicester, 1982; Elliott, 1984,
1990; Stone et al., 1986; van Elst et al., 2000). However, in
several cases, it was a general impression of aggression,
not supported by scientific evidence, and was possibly
influenced by old-fashioned prejudices about epilepsy (de
Boer et al., 2008; Monaco andMula, 2011). In fact, studies
on the true prevalence of aggressive behaviors in people
with epilepsy are scarce.
As stated earlier, psychiatric symptoms in epilepsy
have been historically classified according to their
temporal relation with seizures as peri-ictal, ictal, and
interictal. Ictal symptoms are the clinical expression of
an epileptic seizure. Peri-ictal refers to symptoms
before (preictal) or after (postictal) the seizure, whereas
interictal symptoms are those that occur in no clear
time relationship to the seizures (Table 1).
Peri-ictal aggression is often associated with confu-
sion or psychosis. Although preictal (prodromal) aggres-
sive behavior has been described (Hughes et al., 1993;
Devinsky, 2003), very little detail has been published.
Aggressive behavior has been reported in 22.8% of cases
of postictal psychoses (Kanemoto et al., 2010). Aggres-
sive behavior as an ictal phenomenon is extremely rare.
A large survey of several thousand seizures documented
on video electroencephalograms (EEGs) reported an
incidence rate of 1 in 1000 for aggressive conduct during
seizure (Delgado-Escueta et al., 1981). However, in all of
these cases, violent motor automatisms during seizures
were misinterpreted as threatening or assaultive. In
fact, although the aggressive act may appear orches-
trated, it is poorly directed and does not involve in-
tricate skills or purposeful and detailed behaviors
(Marsh and Krauss, 2000). The aggressive conduct is
directed toward nearby objects or persons, involving
mainly pushing and shoving. Typical epileptic phenom-
ena, such as staring or oral and motor automatisms,
may be present. The patient is usually amnestic
for these episodes, expressing subsequent profound
remorse (Devinsky and Bear, 1984; Herzberg and
Fenwick, 1988; Fenwick, 1989). In the few cases report-
ed from a series in monitoring units, aggressive autom-
atisms were shown to be related to epileptic activity
rising from the amygdala and spreading through the
diencephalic regions (Lee et al., 1998). No clear lateral-
izing features were described, although associated
symptoms point to the nondominant hemisphere (Marsh
and Krauss, 2000). The attribution of violent behaviors
to an ictal event is not always simple, and video-EEG
monitoring always elucidates whether or not behaviors
are associated with a seizure. Treiman (1986) recom-
mended five criteria to determine whether a specific
violent act was the result of an epileptic seizure: 1) the
patient should have an established diagnosis of epilepsy,
2) there should be video-EEG documentation of epileptic
automatisms, 3) there should be video-EEG documenta-
tion of the aggressive behavior, 4) the aggressive act
should be characteristic of the patient’s habitual seizures,
and 5) a clinical judgment should be made by the
neurologist as to the possibility that the violent act was
TABLE 1
Classification of aggressive symptoms according to their temporal relationship with seizures
Timing relative to seizure Aggressive symptoms reported
Peri-ictal
Preictal Not reported
Ictal Aggressive conduct in 1 of 1000 seizures recorded in
monitoring units (Delgado-Escueta et al., 1981)
Postictal Postictal delirium/confusion
Postictal psychoses (22.8% present with aggressive
behaviors)
Paraictal
Forced normalization Rarely reported
Interictal Up to 7% in unselected groups but due to the underlying
psychiatric comorbidity
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part of a seizure (Marsh and Krauss, 2000). These video-
EEG studies also revealed that aggressive behavior
tended to occur as “resistive” violence, typically when an
attendant went to assist the patient during ictal or
postictal confusional states; the implication is that the
patient may have misinterpreted the attendant’s actions
in the patient’s confusional state and may consequently
have resisted aggressively (Treiman, 1986).
Therefore, the available data clearly indicate that
aggressive behavior in epilepsy is most commonly un-
related to seizures themselves. A recent article focusing
on homicide identified 30 articles and 176 cases (pub-
lished up to 2013) involving alleged perpetrators with
epilepsy (Pandya et al., 2013). In 78% of cases, therewas
no temporal relationship between the homicide and the
seizures. In the remaining 22%, the violent episode
occurred as a postictal event in the majority of cases
(82%). Patients were usually young male individuals,
with low average intelligence and a history of behavior-
al problems starting during childhood. Alcohol abuse
and stressful situations were precipitating factors. This
is of interest when we consider psychiatric disorders
associated with aggressive behavior. DSM-5 states that
aggressive behavior can occur in association with
disruptive, impulse control, or conduct disorders or
antisocial personality disorder (American Psychiatric
Association, 2013). These disorders are all character-
ized by problems in emotional and behavioral self-
control and often start during childhood. Data from
the Epidemiology Catchment Area survey reported a
1-year prevalence of violent behaviors of 2.05% (2.7%
and 1.1% for male and female individuals, respectively)
among respondents without any psychiatric disorder
(Swanson et al., 1990). In the large DSM-5 chapter on
impulse control disorders, intermittent explosive disor-
der is the most pertinent in this discussion. It is
characterized by aggressive outbursts that should be
impulse and/or anger based in nature and must cause
marked distress, must cause impairment in occupa-
tional or interpersonal functioning, or must be associ-
ated with negative financial or legal consequences.
According to the DSM criteria (American Psychiatric
Association, 2013), antisocial personality disorder is
defined by a pervasive pattern of disregard for the rights
of other people that often manifests as hostility and/or
aggression. It also starts during childhood. Conduct
disorder is often considered the precursor of the antiso-
cial personality disorder. As for impulse control disor-
ders, patients with antisocial personality disorder
frequently act on impulsive urges without considering
the consequences. This difficulty with impulse control
can result in loss of employment, accidents, legal
difficulties, and incarceration. Remorse is quite com-
mon after behaviors that are the result of poor impulse
control. In contrast, a typical and distinguishing feature
for patients with antisocial personality disorder is the
lack of genuine remorse for the harm they cause others,
although these patients can become adept at feigning
remorse when it is in their best interest to do so.
The lack of data about the prevalence of these
disorders in patients with epilepsy is quite striking.
Despite the huge volume of publications on the contro-
versial issue of personality changes in epilepsy, we
could find no studies that have investigated antisocial
personality disorder or impulse control disorders in
adults with epilepsy; however, it is of interest to note
that in childhood epilepsy, the prevalence of attention
deficit hyperactivity disorder (ADHD; in which impul-
sivity is a core feature) is common, at around 20%–30%
(Hermann et al., 2007).
Studies investigating interictal aggressive symptoms
are also limited. In the 1970s, Rodin (1973) reported the
prevalence of aggressive behavior as 4.3% in unselected
samples of patients with epilepsy, whereas Currie et al.
(1971) reported prevalence of up to 7%. More recently, a
multicenter study using a newly developed question-
naire suggested that people with epilepsy have slightly
less aggressive behaviors than the general population
and that cognitive impairment and polytherapy are
the major associated variables (Piazzini et al., 2011).
However, significantly more aggressive behavior was
present among patients without comorbid psychiatric
disorders than patients with psychiatric comorbidities.
Prevalence rates for aggression were not reported,
because aggressive symptoms were reported as a di-
mension. One research group has investigated the
neuroanatomical correlates of aggressive behavior in
temporal lobe epilepsy (TLE), showing a reduction in
neocortical gray matter in the frontal areas and amyg-
dala atrophy but no association with hippocampal
pathology (van Elst et al., 2000; Woermann et al., 2000).
IV. Neurobiology and Psychopharmacology of
Epilepsy and Aggression
A. Epilepsy and Aggression: Neurobiological and
Neuropharmacological Correlates
Aggressive behavior is one of the psychiatric disor-
ders that has long been described in people with
epilepsy (Kligman and Goldberg, 1975; van Elst et al.,
2000; Sumer et al., 2007). Both the epilepsy itself (Marsh
and Krauss, 2000) and AED use have been suggested as
factors that can increase the risk of aggressive behavior
in patientswith epilepsy. In this section, we examine this
topic from a neurobiological and psychopharmacological
perspective.
The underpinnings of aggression (Siever, 2008;
Comai et al., 2012a) and epilepsy (Engel et al., 2007;
Scharfman, 2007; Moshé et al., 2015) are clearly
multifaceted, and some forms of pathologic aggression
associated with epilepsy have an underlying neurobiol-
ogy that we are only beginning to understand. Although
well characterized and approved pharmacological strat-
egies are currently available for the treatment of the
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different forms of epilepsy (Kwan et al., 2001; Moshé
et al., 2015), national and international guidelines for
the pharmacotherapy of aggression are still controver-
sial and regulatory drug agencies do not presently
consider aggressive behavior as a distinct disease (Comai
et al., 2012b). Consequently, no medication is specifi-
cally approved for the treatment of aggression. One of
the main reasons behind this lack of guidelines is that
the complex neurobiological basis of aggressive behav-
ior has not yet been elucidated by fundamental and
clinical research.
B. Neuropharmacology of Epilepsy
Seizures, at a basic level, originate from an imbal-
ance between excitatory and inhibitory inputs to cells
(i.e., increased excitation or decreased inhibition). The
result is an abnormal synchronization of electrical
activity in a group of active neurons and, depending
on the site of origin and the subsequent brain structures
and networks affected, seizures may produce a variety
of clinical features and symptoms and may remain
localized or generalize across the entire brain. Epilepsy
is a network disorder in which the normal physiologic
connections between cortical and subcortical pathways/
regions are interrupted or disturbed.
The terminology and classification of seizures in
epilepsy is currently under revision. Seizures are
broadly defined as either focal, which originate within
networks in one hemisphere, or generalized, which
originate in and rapidly engage bilaterally distributed
networks (Berg et al., 2010). The older term “partial
onset” is no longer preferred, and the distinctions be-
tween primary and secondarily generalized (i.e., affecting
both hemispheres from the outset, or progressing to both
hemispheres after a focal onset) are not preserved in the
new classification but are still in widespread use. Sei-
zures can then be described in terms of their type (e.g.,
generalized tonic–clonic, absence,myoclonic, clonic, tonic,
or atonic) and by their underlying cause (genetic versus
structural/metabolic versus unknown). Many syndromes
are also defined, such as juvenile myoclonic epilepsy and
Lennox–Gastaut syndrome, which are characterized by
complex and specific clinical features, signs, and symp-
toms that frequently cluster together (Berg et al., 2010).
At a cellular level, the electrical activity of neurons is
under the control of ion transporters, pumps, and ion
channels, which allow amounts of positively or negatively
charged ions to flow in and out of cells. In turn, these
pumps and ions channels are regulated by factors such as
voltage or the binding of ligands either directly or via G
protein–coupled receptors (Kandel et al., 2000; Dascal,
TABLE 2
AED targets and effect on aggression in patients without epilepsy
Missing data do not necessarily imply that there is no action on a specific target. In particular, research on the effects of novel and recent AEDs on epigenetic regulation
and/or gene expression is still ongoing. Unless otherwise specified, mechanism-of-action details may be found in the text of this review, in review articles (Rogawski and
Löscher, 2004; Brodie, 2010; Comai et al., 2012b), and/or in the summary of product characteristics for each individual AED.
AED Main System Targeted Other PossibleSystems Targeted
Epigenetic Mechanisms/
Gene Expression
Antiaggressive in
Psychiatric Patientsf
Carbamazepine Na+ channels X X
Eslicarbazepine acetate Na+ channels Xb
Lacosamide Na+ channels
Lamotrigine Na+ channels Glutamate (AMPA receptors) X X
Oxcarbazepine Na+ channels X
Phenytoin Na+ channels Xc X
Rufinamide Na+ channels
Zonisamide Na+ and Ca2+ channels GABA Xd
Ethosuximide T-type Ca2+ channels
Gabapentin Ca2+ channels GABA, glutamate (NMDA
receptors)
X
Pregabalin Ca2+ channels GABA
Retigabine K+ channels GABAa
Felbamate Mixed Ca2+ channels, NMDA receptors,
GABA receptors
Topiramate Mixed GABAA receptors, AMPA/kainate
receptors, Na+/Ca2+ channels
X X
Phenobarbital GABA
Clobazam/clonazepam GABA (GABAA receptor) X
Vigabatrin GABA Xe
Tiagabine GABA X
Stiripentol GABA
Levetiracetam Neurotransmitter release (via SV2A) X X
Brivaracetam Neurotransmitter release (via SV2A)
Perampanel Glutamate (AMPA receptors)
Valproic acid Mixed GABA, glutamate (NMDA, AMPA,
and kainate receptors), Na+
channels
X X
aTreven et al. (2015).
bDezsi et al. (2013).
cHassel et al. (2010).
dUeda et al. (2012).
eTran et al. (1999).
fComai et al. (2012b), Gallagher and Herrmann (2014), and Huband et al. (2010).
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2001; Bean, 2007). The pivotal channels in these process-
es areNa+, K+, Ca2+, andCl2 channels, which are also the
target of many of the current available AEDs (Table 2).
The major excitatory and inhibitory neurotransmit-
ters are glutamate and GABA, respectively (Kandel
et al., 2000), and these neurotransmitter systems are
also targeted by many other AEDs (Table 2). Mono-
amines including serotonin (5-HT), dopamine (DA), and
noradrenaline (NA) represent another group of neuro-
active compounds that regulate neural activity and thus
could influence the initiation and spread of seizure
activity (Starr, 1996; Giorgi et al., 2004; Stefulj et al.,
2010); however, these are not primarily targeted by any
current AEDs.
C. Neurobiology and Neuropharmacology
of Aggression
Aggression is a complex behavior governed by several
cortical and subcortical brain networks that are modu-
lated by neurotransmitter systems, including mono-
amines, glutamate, and GABA, and by ion channels
(Gedye, 1989; Sumer et al., 2007). The neurobiological
impairments observed in aggression occur at genomic
and transcriptional levels as well as at the level of the
synthesis and the metabolism of various neurotrans-
mitters and their receptors. The main receptors and
enzymes involved in theneurobiology of aggression,which
are also targeted by antiaggressive medications, include
those involved in monoamine neurotransmission–
serotonin5-HT1Aand5-HT2Areceptors, 5-HTtransporters,
DA D1 and D2 receptors, DA transporters, a1- and
a 2-adrenoceptors, the enzyme monoamine oxidase
(MAO)-A, the GABA system (GABAA and GABAB
receptors and GABA transaminase), the glutamate
NMDA and AMPA receptors, and voltage-gated Na+
and Ca2+ channels (Siever, 2008; Comai et al., 2012a)
(Fig. 1). Genetic and epigenetic regulation of these
neurotransmitters, channels, and enzymes as well as
the intracellular events after their cell activation/
deactivation is also involved in aggressive behavior
(Comai et al., 2012a). For example, polymorphic variation
in the gene for MAO-A (Manuck et al., 2000) and MAO-A
gene promoter hypermethylation, which causes a down-
regulation of MAO-A activity (Checknita et al., 2015),
have been associated with aggressive behavior.
At a structural level, the study of brain lesions, brain
injury, and imaging techniques has identified several
regions as important in the pathophysiology of aggres-
sion, particularly the amygdala, hippocampus, and
frontal lobes (Bannon et al., 2015). At a functional level,
positron emission tomography and single-photon emis-
sion computed tomography imaging studies suggest
that the ventromedial cortex, limbic system, amygdala,
and thalamus are involved in impulsivity and aggres-
sion; in particular, reduced activity in the medial tempo-
ral subcortical lobe has been demonstrated (reviewed
by Soyka, 2014). In the search for possible imaging
biomarkers of aggression, a reduced gray matter volume
at the level of the orbitofrontal cortex and low amygdala
volume have both been linked with predisposition to
violence (Matthies et al., 2012; Pardini et al., 2014;
Bannon et al., 2015).Collectively, although brain imaging
studies have revealed important information about the
neuroanatomy underlying aggressive and impulsive be-
havior, this knowledge cannot yet be used to predict
aggression in humans (Razafsha et al., 2015). In the
future, imaging studies inpatientswith epilepsy inwhom
aggression develops orworsens afterAED treatmentmay
help identify brain abnormalities associated with
epilepsy and aggression and may identify prognostic
markers of aggression in patients with epilepsy.
D. Networks and Neurotransmitters Common to
Epilepsy and Aggression
EEG changes during seizures and their clinical
manifestation reflect the localization of the seizure
activity (Engel et al., 2007); subcortical structures (in-
cluding the thalamus and brain stem) may play a
crucial role in the propagation and behavioral manifes-
tations of epileptic seizures rather than just being a site
of seizure origin (Norden and Blumenfeld, 2002).
1. Temporal Lobes and Hippocampus. One of the
most common and studied forms of focal epilepsy is
TLE. Seizures originate in the temporal lobes (either
the inner surface/structures or more rarely the neo-
cortex) and can be associated with psychiatric symp-
toms, including mood changes and aggressivity (Zhao
et al., 2014). The temporal lobe is also important in
aggression; in milestone research by Klüver and Bucy
(1937), bilateral temporal lobectomy in rhesus monkeys
reduced aggression. The temporal lobe is part of the
limbic system that controls emotions and memory, and
subjects with histories of extremely violent behavior
have shown metabolic abnormalities in the temporal
lobes (Seidenwurm et al., 1997); functional and/or
structural abnormalities in neural networks regulating
emotions have been related to an increased susceptibil-
ity for impulsive aggression and violence (Davidson et al.,
2000). TLE is often associated with an extensive loss of
dentate hilar neurons and hippocampal pyramidal cells—
the so-called “hippocampal sclerosis” (Sloviter, 1994)—
and interestingly, hippocampal pathology has been
identified in pathologic aggression (as discussed later).
2. Amygdala. The amygdala has been implicated in
epilepsy, particularly in TLE and epileptogenesis, since
the landmark studies by Feindel and Penfield (1954)
and later byGoddard et al. (1969). Since this early work,
many studies have shown that different forms of epilepsy
are associated with damage to the amygdaloid complex
(23 distinct subnuclei in humans) and to its connectivity to
the surrounding brain regions and to the cortex (Pitkänen
et al., 1998; Tebartz Van Elst et al., 2002; Takaya et al.,
2014). The amygdala is also implicated in aggressive
behavior: amygdalectomy in both animals and humans
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can stop aggressive behavior (Terzian and Ore, 1955),
and stereotactic amygdalotomy of specific amygdaloid
nuclei (e.g., the lateral or the anteromedial group) has
been shown to control behavior in highly aggressive,
treatment-refractory individuals (Mpakopoulou et al.,
2008).
3. Frontal Lobes. Frontal lobe epilepsy, the second
most common type of focal epilepsy, is also associated
with aggressive behavior during and after seizures
(Gedye, 1989; Sumer et al., 2007). Damage to the frontal
lobes is implicated in violent and aggressive behavior:
patients with frontal ventromedial lesions consistently
Fig. 1. Schematic representation of brain targets common to the neurobiology and pharmacology of epilepsy and aggression. All of the targets
illustrated in the figure are described in the main text. (A) Example of a prototypical excitatory (glutamate)/inhibitory (GABA) synapse modulating the
activity of a forebrain postsynaptic neuron. Postsynaptic targets include glutamate (NMDA, AMPA, and kainite receptors) and GABAA receptors. SV2A
is a membrane glycoprotein that regulates neurotransmitter release from secretory vesicles. Voltage-gated K+, Na+, and Ca2+ channels modulate the
action potential and resting membrane potential thus controlling neuronal firing activity. GABA transaminase catabolizes GABA into succinic
semialdehyde. (B) Schematic representation of synaptic interactions between 5-HT, norepinephrine, and DA neurons with their projections to the
forebrain postsynaptic neurons. On the presynaptic level, the autoreceptors mediating the inhibitory action of these three neurotransmitters are
indicated. Notably, autoreceptors are targets for aggression treatment. The a2-adrenoceptor agonist clonidine is used to manage aggression, the D2
autoreceptor antagonist haloperidol is an antipsychotic with antiaggressive properties, and the 5-HT1A autoreceptor agonist eltoprazine has
demonstrated potent antiaggressive properties in preclinical studies. The enzyme MAO, which catabolizes the monoamines DA, norepinephrine, and 5-
HT, is located on the outer membrane of mitochondria, and MAO inhibitors are widely used in mood disorders. On the postsynaptic level, the
monoaminergic receptor subtypes implicated in the pathophysiology and pharmacology of epilepsy and aggression are indicated. (C) A schematic
simplification of the Akt/GSK3 and mTOR signaling pathways is shown; these pathways are regulated by G protein–coupled receptors, which may be
involved in the neurobiology and in the treatment of both aggression and seizures. Furthermore, processes in the nucleus have also been implicated in
aggression and epilepsy: DNA transcription, and epigenetic modifications of DNA such as methylation of the C-5 position of the cytosine ring, and
histone modification (deacetylation of histones by histone deacetylases). GSK3, glycogen synthase kinase 3; HDAC, histone deacetylase; Me,
methylation; mTOR, mammalian target of rapamycin.
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demonstrated higher rates of aggression/violence
(especially verbal confrontations) than patients with
lesions in other brain areas (Grafman et al., 1996).
Motor agitation and aggressive behavior have also been
shown in patients with orbitofrontal seizures (Tharp,
1972), further supporting the role of dysfunction in this
brain region in aggression (Giancola, 1995).
4. Hypothalamus. Other brain areas that are impli-
cated in the pathophysiology of aggressive behavior and
are components of emotional regulation circuits include
the anterior cingulate cortex, amygdala, hypothalamus,
septal nuclei, and periaqueductal gray matter of the
midbrain (Fig. 2). The hypothalamus is an important
part of the diencephalon that is implicated in both
epilepsy and aggression. Studies in cats have shown
that the hypothalamus, particularly the anteriormedial
hypothalamus, is involved in the modulation of de-
fensive rage behavior (Gregg and Siegel, 2001). A
positron emission tomography study in humans found
low hypothalamic activity in male perpetrators of
domestic violence and decreased correlations between
cortical and subcortical brain structures (George et al.,
2004). Anterior hippocampal asymmetries have been
demonstrated in antisocial and violent subjects (Raine
et al., 2004), and an inverse correlation was shown
between hippocampal gray matter volume and lifetime
aggression in borderline personality disorder (Zetzsche
et al., 2007).
Taken together, it is clear that neurobiological net-
works that are important in epilepsy are also common
neural substrates implicated in aggressive behavior. A
summary of the networks and brain regions that are
important in both epilepsy and aggression is shown in
Fig. 2.
Within these brain regions and networks, the recep-
tors and ion channels that are implicated in both
epilepsy and aggression are also the targets of AEDs
and mood stabilizers. In addition, alterations at the
level of intracellular signaling cascades, gene sequence,
or gene expression have been shown in both epilepsy
and aggression in these areas.
5. GABA. Clinical and preclinical studies have
shown that seizures are liable to occur with an increase
in glutamate and/or decrease in GABA neurotransmis-
sion in the brain. However, the changes in glutamate
and/or GABA levels are different in different types of
epilepsy, animal models, and brain regions (Engel et al.,
2007). GABAA receptors are ligand-gated chloride ion
channels and are the major inhibitory receptors in the
central nervous system (Olsen and Tobin, 1990). Houser
et al. (2012) have extensively reviewed GABAA receptor
expression, subunit composition, and function in epi-
lepsy. Changes in GABAA receptor expression and
function have been reported in animal models of TLE
(Peng et al., 2004), and the composition and function of
GABAA receptors changes not only in epilepsy but also
after prolonged exposure to GABAA allosteric modula-
tors such as the AEDs diazepam and phenobarbital
(Raol et al., 2005).
GABA neurotransmission has been also been inves-
tigated in the pharmacology and pathophysiology of
aggression (Comai et al., 2012a). The situation is
complex, and there is no clear agreement on whether
GABA levels are decreased or increased in aggression,
or whether enhancing GABA is anti- or proaggressive.
For example, Bjork et al. (2001) found a negative
correlation between plasma GABA levels and aggres-
siveness in psychiatrically healthy people with a family
history of depression, whereas Lee et al. (2009) reported
a positive correlation between GABA levels in the
cerebrospinal fluid and impulsivity (but not aggression)
in both nonmedicated normal controls and subjects with
Fig. 2. Brain regions that are important in both epilepsy and aggression. Schematic rendering of brain regions and nuclei involved in the neurobiology
of both epilepsy and aggression. The role of each highlighted brain region/nuclei in epilepsy and aggression is discussed in the main text.
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personality disorder. Allosteric modulators of GABAA
receptors, including barbiturates and benzodiazepines,
have been shown to influence aggression levels in rodents
with an invertedU-shaped dose-response curve:moderate
doses induce aggression,whereas low or high doses reduce
aggressive behavior (Miczek et al., 2002).
6. Glutamate. Glutamate is the principal excitatory
neurotransmitter in the brain. It acts through iono-
tropic (NMDA, AMPA, and kainite) and metabotropic
receptors and plays a significant role in the initiation,
spread, and maintenance of epileptic activity. Research
has demonstrated that epilepsy is linked to dysfunction
of the glutamate system at different levels: genetic,
neurotransmitter release, and receptor expression
(Bradford, 1995; Barker-Haliski and White, 2015).
Studies have reported increased plasma levels of gluta-
mate in epilepsy (van Gelder et al., 1980; Janjua et al.,
1992) and sustained increases in extracellular glutamate
levels during seizures in the epileptogenic hippocampus
(During and Spencer, 1993). Focal brain cooling, which
can suppress epileptic seizures in refractory epilepsy, has
been shown to significantly decrease glutamate levels in
patients who have elevated glutamate in the cortex and/
or hippocampus during seizures (Nomura et al., 2014).
Glutamate is cleared from synapses by the membrane
glutamate transporters and is loaded into synaptic
vesicles by the vesicular glutamate transportersVGLUT1,
VGLUT2, and VGLUT3 (El Mestikawy et al., 2011). A
recent postmortem study comparing VGLUT expression
in the hippocampus found significantly decreased
VGLUT2 expression and significantly increased VGLUT3
expression in patients with TLE with hippocampal
sclerosis, comparedwith autopsy controls (Van Liefferinge
et al., 2015). Glutamate receptors, both ionotropic and
metabotropic, have been extensively studied for their
role in epilepsy in both human and animal studies
(Moldrich et al., 2003; Ghasemi and Schachter, 2011;
Szczurowska and Mares, 2013). Glutamate receptors
are targeted selectively and nonselectively by several
AEDs (Table 2), and novel glutamate receptor ligands
are also under development as potential AEDs (Löscher
et al., 2013; Nicoletti et al., 2015).
Attention was initially directed toward antagonists of
NMDA receptors, but they failed in several clinical
trials (Rogawski, 2011). Interestingly, the NMDA an-
tagonists phencyclidine (PCP) and ketamine have pro-
convulsant action at very high doses and anticonvulsant
properties at low doses (Leccese et al., 1986). Research
then moved to AMPA receptors (Rogawski, 2011), and
2012 saw the approval of the first selective AMPA
receptor antagonist, perampanel, for the treatment of
focal seizures. The role of kainate receptors in the
pathophysiology of epilepsy is becoming better under-
stood, particularly in TLE, and this was recently
reviewed (Crépel and Mulle, 2015). Kainate receptors
are located either presynaptically at both GABAergic
and glutamatergic synapses, where they control
neurotransmitter release and are involved in presyn-
aptic plasticity (Schmitz et al., 2001), or postsynapti-
cally in several regions deeply involved in epilepsy,
including the cortex, hippocampus, and amygdala
(Crépel and Mulle, 2015).
Few studies thus far have investigated the role of
glutamate in aggression (Comai et al., 2012a); however,
there is strong evidence of the involvement of glutamate
in the pathophysiology and treatment of mood disorders
such as depression (Kugaya and Sanacora, 2005; Niciu
et al., 2014) that often coexist with aggressive behavior.
Support for the glutamate hypothesis of aggression
includes the demonstration of a positive relationship
between cerebrospinal fluid glutamate levels and
measures of impulsive aggression in both healthy
human subjects and subjects with personality disorders
(Coccaro et al., 2013). Studies in mice with genetic
modifications at the levels of the genes encoding for the
NMDA and AMPA receptors have shown altered levels
of aggression in the resident intruder test (Brodkin
et al., 2002; Duncan et al., 2004; Vekovischeva et al.,
2004), an animal paradigm of aggressive behavior,
suggesting a role for glutamate ionotropic receptors in
aggression in rodents. In mice, the NMDA receptor
channel blocker PCP produces a nonsignificant trend
toward increased aggressiveness at low doses, whereas
it seems to reduce aggression at high (near ataxic) doses
(Belozertseva and Bespalov, 1999). The fact that med-
ications that can decrease aggression (e.g., valproic acid
and topiramate) have inhibitory effects at NMDA and
AMPA receptors (Comai et al., 2012b) provides further
supportive evidence for the involvement of glutamate in
aggression; however, the association of these same
AEDs with aggression in some patients with epilepsy
shows that the mechanisms are complex.
7. Serotonin. Bonnycastle et al. (1957) were the first
to demonstrate a link between anticonvulsant activity
and 5-HT, showing that several AEDs, including phe-
nytoin, significantly increased 5-HT levels. Pharma-
cological agents that elevate 5-HT levels (e.g., the
selective serotonin reuptake inhibitor fluoxetine and
5-hydroxytryptophan) have anticonvulsant effects in
several animal models of epilepsy (Pasini et al., 1992),
whereas agents that reduce and/or deplete 5-HT (e.g.,
parachlorophenylalanine, a selective and irreversible
inhibitor of tryptophan 5-hydroxylase) increase suscep-
tibility to sound-induced seizures (Schlesinger et al.,
1968). 5-HT receptors are expressed in almost all
networks involved in epilepsy. With the exception of
5-HT5 receptors, for which there is no evidence yet of
involvement in epilepsy, Gharedaghi et al. (2014) re-
cently reviewed and commented on the role of each 5-HT
receptor subtype in epilepsy and seizure susceptibility.
Activation of 5-HT1A receptors is anticonvulsant in
various experimental seizure models. A study adminis-
tering a 5-HT1A agonist in lithium-pilocarpine–induced
status epilepticus in mice showed that hippocampal
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5-HT1A receptors are involved in reducing seizure
severity, whereas those located in extrahippocampal
areas contribute to delayed seizure propagation (Yang
et al., 2014). In patients with TLE, decreased 5-HT1A
receptor binding has been observed in the midbrain
raphe, the ipsilateral thalamus, and the inferior region
of the epileptogenic temporal lobe (Toczek et al., 2003).
Genetic inactivation of 5-HT2C receptors in mice pro-
duces rare spontaneous seizures that are occasionally
fatal (Heisler et al., 1998).
5-HT has a central role in aggression and hundreds of
articles have examined this topic since the early 1960s.
It was believed that 5-HT generally inhibits aggression
but recent findings challenge this hypothesis, showing
that this may be limited to certain types of aggression,
such as impulsive aggression, or perhaps instead to
factors such as impulse control and emotion regulation
(Krakowski, 2003). For example, the main metabolite
of 5-HT, 5-hydroxyindoleacetic acid, is reduced in the
cerebrospinal fluid of people with demonstrated auto- or
heteroaggressive behavior compared with people who
have never shown such behavior. These observations
were made in suicidal individuals (Asberg et al., 1976),
in nondepressed men with a history with aggressive
behavior (Brown et al., 1979), violent men in prison
(Linnoila et al., 1983), in impulsive arsonists (Virkkunen
et al., 1987), and in patients with a personality disorder
(Coccaro et al., 1989). The 5-HT1A/1B agonist eltoprazine
is considered a potent antiaggressive agent (Comai
et al., 2012a).
8. Dopamine. The role of DA in epilepsy is still
debated, although there is evidence of dopaminergic
system involvement in certain animal models of epi-
lepsy and in various forms of epilepsy in humans (Starr,
1996). In particular, alterations of subcortical dopami-
nergic pathwaysmay be specifically related to themotor
manifestations of certain types of seizures (Norden and
Blumenfeld, 2002).
In general, DA seems to exert an antiepileptic action,
as demonstrated by the fact that the nonselective D1/D2
agonist apomorphine, with certain limitations, has
anticonvulsant properties, whereas neuroleptic drugs
that act as D1 and/or D2 antagonists have predomi-
nantly proconvulsant actions. This is important, be-
cause some medications used to control aggression are
D1 and/or D2 antagonists (Comai et al., 2012b). Looking
at the role of specific DA receptors in epilepsy, evidence
fromboth animal (Turski et al., 1988; al-Tajir et al., 1990)
and human (Ring et al., 1994) studies has implicated D2
receptors.
The dopaminergic system is mainly implicated in
behavioral activation, motivated behavior, and reward
processing (Ikemoto and Panksepp, 1999), but evidence
suggests that it also modulates aggressive behavior.
Cerebrospinal fluid levels of homovanillic acid, the final
metabolite of DA, are lower in impulsively aggressive
violent offenders with antisocial personality disorder
than in nonimpulsively aggressive offenders with para-
noid or passive-aggressive personality disorder (Linnoila
et al., 1983). DA receptor antagonists (particularly
conventional antipsychotics that target D2 receptors,
such as haloperidol) have been used effectively for
decades to treat aggression in psychotic patients. Even
though DA has been hypothesized to be necessary for
aggressive behavior to occur, reflecting the motiva-
tional aspect of violence (Nelson and Chiavegatto,
2001; de Almeida et al., 2005), the exact role of DA in
aggression is still unclear (Comai et al., 2012a).
9. Noradrenaline. Endogenous NA seems to be gen-
erally antiepileptic:NA levels are decreasedafter seizures,
depending on the seizure type and brain region (Giorgi
et al., 2004), and AEDs such as valproic acid increase NA
levels in the rat (Baf et al., 1994). The antiepileptic
actions of NA are very likely mediated by both a1- and
a2-adrenoceptors; indeed, a2-adrenoreceptor agonists
have been shown to suppress, and a2-adrenoreceptor
antagonists to promote, seizures in kittens (Shouse
et al., 2007).
In aggression, NA seems to play a permissive role,
helping to determine whether an individual elects to
fight or flee in response to a challenge (Miczek and Fish,
2005). Studies have explored the effects of an experi-
mental depletion or increase of NA levels, as well as
activation or inhibition of NA receptors, on aggression.
However, research is still limited and no clear positive
or negative correlation has yet been demonstrated.
Some studies report reduced fighting tendency after
depletion of brain NA in male mice with isolation-
induced fighting as well as after intraventricular in-
jection of 6-hydroxydopamine (Crawley and Contrera,
1976). Some studies, in contrast, report increased
aggression (shock-induced fighting) after NA depletion
in rats (Thoa et al., 1972). The role of a2-adrenoceptors
is important in mediating the effects of NA manipula-
tions on aggression. For example, increasing NA levels
with desipramine (a NA reuptake blocker) increases
isolation-induced aggression inmice in a dose-dependent
manner, and the a2-adrenoceptor blocker yohimbine
dose-dependently counters this increase (Matsumoto
et al., 1991). In addition, the a2-adrenoceptor agonist
clonidine, which decreases NA neuronal activity by
activatingNAautoreceptors, has been shown to decrease
pathologic aggression in humans and is used in clinical
settings in irritable autistic children, children with
conduct disorder (Fava, 1997), and also in adults with
aggression (Comai et al., 2012b). Clonidine is also of
value in treating ADHD in children, particularly those
with conduct or oppositional defiant disorder (Connor
et al., 1999, 2000).
10. Intracellular Signaling Cascades, Genes, and
Epigenetic Gene Regulation in Epilepsy and Aggression.
The role of intracellular events (e.g., intracellular
proteins and signaling cascades, genes and epigenetic
modifications) is another important framework in
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which to consider in the neurobiology of epilepsy and
AED development (Löscher et al., 2013).
The study of intracellular cascade events after receptor
activation has been actively researched in epilepsy. In
the pilocarpine-induced status epilepticus model, for
example, increased phosphorylation of the mitogen-
activated protein kinases (MAPKs) extracellular signal-
regulated kinase (ERK)-1, ERK2, and p38MAPK has been
demonstrated in the acute period (up to 12 hours after
status epilepticus) and protein kinase B in the latent
period (5 days after pilocarpine-induced status epilepti-
cus) (Lopes et al., 2012). These biochemical changes in
the serine-threonine kinases, which are implicated in
neuronal survival and differentiation as well as neuro-
plasticity, may in turn alter gene expression and produce
long-lasting neuronal changes. However, ERK signaling
has multiple roles during epilepsy-related processes; its
activation can contribute to acute seizure activity and
might be necessary for epileptiform synchronization
(Houser et al., 2008). Themammalian target of rapamycin
is a regulator of mRNA translation that is itself regu-
lated by ERK and protein kinase B (Li et al., 2010). As
reviewed by Cho (2011), there is evidence to implicate
abnormal activity of signaling molecules in the mamma-
lian target of rapamycin pathway in epilepsy.
There has been less research on the intracellular
signaling cascades underlying aggressive behavior.
However, because these cascades (and the G protein–
coupled receptors that activate them) are targeted by
medications used to treat aggression (Beaulieu, 2012), it
is reasonable to hypothesize their active involvement in
the pathophysiology of aggression (Comai et al., 2012a).
Aggressive behaviors are common among abusers of
methamphetamine, and repeated injections of metham-
phetamine in mice have also been shown to increase
aggressive behavior (Sokolov and Cadet, 2006). In these
animals, there were significant alterations in the
expression of proteins involved in MAPK-related path-
ways in the striatum and frontal cortex (Sokolov and
Cadet, 2006).
Regarding the specific involvement of genes in both
epilepsy/seizure susceptibility and aggressive behavior,
studies have been very limited in number. Two genes
that have been implicated in both seizures and aggres-
sion are the gene encoding the MAO-A enzyme and that
encoding the 5HT1B receptor. Complex changes in
seizure susceptibility are seen in MAO-A knockout
mice, which have high levels of 5-HT and NA. After
pentylenetetrazol kindling, the latency to seizure de-
velopment is shorter in knockout mice than in wild-type
mice; however, the knockout mice then have fewer
seizures per day and shorter-duration seizures com-
pared with wild-type mice, suggesting some protective
effect despite the increased susceptibility to kindling
(Teskey et al., 2004). Regarding aggressive behaviors,
MAO-A knockout mice are more aggressive than wild-
type mice, displaying decreased latency to attack in the
resident intruder test (Cases et al., 1995). The only
study in humans that explored links between epilepsy
and polymorphisms in the gene encoding MAO-A was
negative, but the study was underpowered to detect
minor differences (Stefulj et al., 2010). The same study
instead showed amodest association between the G861C
polymorphism in the 5-HT1B receptor gene and TLE.
Notably, a 5-HT1B polymorphism has been associated
with suicide history and personality disorder in humans
(New et al., 2001) and 5-HT1B knockout mice display
increased levels of aggression in the resident intruder
test (Bouwknecht et al., 2001).
Epigenetic factors, including seizures themselves and
AEDs, can alter neural network dynamics by interfer-
ing with signaling pathways and enzyme and receptor
expression. Epilepsy can be influenced not only by
alterations in genetic and environmental factors but
also by a spectrum of dysfunctional epigenetic factors
and processes (Qureshi and Mehler, 2010; Kobow and
Blümcke, 2014). Indeed, hundreds of misregulated
genes have been identified in human and experimental
models of epilepsy after epigenetic chromatin modifica-
tions and DNA methylation. Modifications, such as
DNA methylation, may accumulate over time after an
initial injury, and a methylation hypothesis of epilepsy
has been proposed (Kobow and Blümcke, 2012); such
epigenetic changes may explain interindividual differ-
ences in the emergence of epilepsy, such as after
brain trauma (Machnes et al., 2013). Interestingly, the
AED valproic acid has been shown to inhibit histone
deacetylases and thereby normalize expression of his-
tone deacetylase–dependent genes within the epileptic
dentate area in rats with kainic acid–induced seizures
(Jessberger et al., 2007).
The epigenetic modifications involved in aggressive
behavior have not been well studied. Evidence thus far
demonstrates a relationship between epigenetic modi-
fications in the 5-HT system and aggression. In a recent
study, we found decreased MAO-A activity in antisocial
offenders, resulting from epigenetic modifications in
MAO-A gene methylation levels (Checknita et al.,
2015). Methylation levels of the 5-HT transporter gene
promoter (SLC6A4) were also shown to be altered in
individuals displaying physical aggression during child-
hood (Wang et al., 2012).
E. Pharmacological Targets of Antiepileptic Drugs for
Epilepsy and Aggression
The pathophysiology of epilepsy is multifaceted, in-
volving several neurotransmitter systems and many
receptors, ion channels, intracellular signaling cascades,
genes, and epigenetic modifications (Engel et al., 2007;
Scharfman, 2007; Moshé et al., 2015). Several of these
possible mechanisms are targeted by current AEDs and
are being targeted by new drug development. As shown
in Table 2, themajority of current AEDs target primarily
either the classic voltage-gated ion channels (Na+, K+,
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andCa2+) or theGABAsystem,whereasmanyAEDshave
mixed mechanisms and others selectively inhibit other
targets (e.g., neurotransmitter release by levetiracetam,
AMPA receptors by perampanel) (Rogawski and Löscher,
2004; Brodie, 2010; Comai et al., 2012b).
Modulation of genes and epigenetic mechanisms by
AEDs has also been reported in recent years (Comai
et al., 2012a,b). Levetiracetam has a clear and distinct
mechanism of action; it acts on the SV2A integral
membrane glycoprotein present on all synaptic vesicles
(Lynch et al., 2004). Recent work by Vogl et al. (2015) in
superior cervical ganglion neurons demonstrated that
SV2A maintained normal neurotransmission by regu-
lating readily releasable pool size, had a facilitatory role
in recovery from synaptic depression, and impaired
presynaptic voltage-dependent Ca2+ channel current
density. Specific details on the mechanisms of action of
AEDs at the level of receptors and ion channels have
been extensively reviewed (Kwan et al., 2001; Löscher
et al., 2013; Moshé et al., 2015).
Many AEDs are also used to treat aggression in
psychiatric populations, such as patients with schizo-
phrenia, schizoaffective disorders, bipolar disorders,
and autism spectrum disorders (Comai et al., 2012b).
AEDs such as valproic acid, topiramate, gabapentin,
and lamotrigine are frequently used, as are those
targeting ion channels, including carbamazepine, oxcar-
bazepine, lamotrigine, and phenytoin (Comai et al.,
2012b) (Table 2).
The atypical antipsychotics clozapine, olanzapine,
quetiapine, and risperidone as well as the conventional
antipsychotic haloperidol, which are high-affinity an-
tagonists at 5-HT2A and/or 5-HT1A receptors and D2
receptor antagonists, are also widely used “off-label” to
attenuate aggressive behavior (Gobbi et al., 1999;
Comai et al., 2012b). The rationale derives from the
abnormalities of 5-HT and DA systems in the patho-
physiology of aggressive behavior (Comai et al., 2012a).
Clozapine has been demonstrated to be superior to
olanzapine and haloperidol in the control of aggression
(Volavka et al., 2004). In more resistant cases, the
combination of clozapine and an AED such as valproic
acid remains the most effective treatment (Gobbi and
Debonnel, 2003).
F. Conclusions: Why Might Antiepileptic Drugs Induce
Aggressive Behavior in Epilepsy?
There is a complex comorbidity between aggression
and epilepsy and as we have shown in this section,
aggression and epilepsy also have complex and over-
lapping pathophysiology. In the following sections, the
evidence for a link between aggressive behavior and
AEDs in people with epilepsy is reviewed. A critical
question is, therefore, how can an AED apparently
precipitate aggression in some people with epilepsy
but improve aggressive behaviors in other people?Here,
we discuss some speculations and hypotheses on this
topic, based on common neurobiological correlates be-
tween epilepsy and aggression.
1. Paradoxical Proaggressive Effects of Enhancing
GABA Neurotransmission. The GABA system has the
potential for both inhibitory and excitatory actions. In
the neonatal brain, GABA is excitatory and not in-
hibitory, due to the high intracellular concentration of
chloride (Ben-Ari and Holmes, 2006). In the mature
brain, rhythmic afterdischarge of pyramidal CA1 cells
after cessation of the stimulus relies on a powerful
GABAA-mediated excitation mechanism (Fujiwara-
Tsukamoto et al., 2003). In adults with TLE, the
morphology, hippocampal expression, and subcellular
distribution of GABAA receptor subunits is markedly
altered (Loup et al., 2000) and, in mature neurons,
recurrent and prolonged seizures may trigger a patho-
logic re-emergence of immature excitatory features
of GABAA receptors (Galanopoulou, 2008). Moreover,
TLE is often characterized by hippocampal sclerosis
and thus depletion of GABAergic interneurons and
glutamatergic hilar mossy cells, by mossy fiber (with
colocalization of GABA and glutamate receptors) sprout-
ing and synaptic reorganization in the dentate gyrus
(Jinde et al., 2013). We hypothesize that in the epileptic
brain,manymodifications inGABA receptors andGABA-
ergic neurons can occur, such that agents enhancing
GABA neurotransmission (which decrease aggressive
behaviors in subjects without epilepsy) can, depending
on the brain region, have the opposite effect of triggering,
rather than decreasing, aggression.
2. Dose-Dependent and Opposite Effects of NMDA
Receptor Antagonists on Epilepsy and Aggression.
The glutamatergic system, like the GABA system, may
have dose-dependent opposite effects. Depending on the
dose, NMDA receptor blockers such as PCP appear
to have both pro- and antiepileptic as well as pro-
and antiaggressive properties (Leccese et al., 1986;
Belozertseva and Bespalov, 1999). In particular, PCP
at low doses is antiepileptic but proaggressive, whereas
the opposite is observed at high doses. Increased
aggression might consequently occur when AEDs that
have an NMDA receptor–inhibitory component to their
action are used at doses that have minimal NMDA
receptor antagonism. Some subtypes of epilepsy, such
as TLE, can be associated with a reshaping of gluta-
matergic neurons and receptors in the hippocampus;
consequently, drugs blocking glutamatergic receptors
may have a different or opposing effect in the epileptic
brain than in nonepileptic brains.
3. Genetic Predisposition and Decreased Dopaminer-
gic Activity. A recent association study set out to
explore whether there was a genetic basis that predis-
poses some patients to develop behavioral AEs during
levetiracetam treatment. Helmstaedter et al. (2013)
identified several polymorphisms, all of which were
associatedwith reduced dopaminergic activity (variations
in DA-b-hydroxylase, catechol-O-methyltransferase, and
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an intracellular D2-receptor binding protein), which
seem to predispose patients with epilepsy treated with
levetiracetam to develop aggression. It is not yet known
whether this result is specific to levetiracetam, or whether
reduced dopaminergic activity will predispose patients
with epilepsy to behavioral AEs with other AEDs
4. Forced Normalization. Finally, the sometimes
controversial forced normalization theory is an attempt
to explain the occasional observation of a paradoxical
inverse relationship between epileptiform abnormality
in EEGand psychiatric symptoms. It was first described
in 1953 by Heinrich Landolt, who observed that EEGs
paradoxically normalized and seizure activity was
inhibited during psychotic episodes (Landolt, 1953).
The forced normalization phenomenon is similar to but
distinct from the concept of the “alternative psychosis”
or “reciprocal psychosis” (that psychosis is better when
seizures are worse and psychosis is worse when
seizures are better/controlled, as discussed later). This
hypothesis was supported by epidemiologic studies
that found lower seizure frequency in patients with
epilepsy and psychosis, and studies reporting relative-
ly few cases involving comorbid schizophrenia and
epilepsy (Schmitz and Trimble, 1992). This observa-
tion can be extended to psychiatric phenomena other
than psychosis, such as hypomania/mania, aggression,
depression, and anxiety (Trimble and Schmitz, 1998).
Therefore, the psychiatric adverse effects seen during
AED treatment may not be a direct adverse psycho-
tropic effect of the AED, but rather a consequence of
the suppression of seizures. This inverse link between
seizure control and psychiatric symptoms (Flor-Henry,
1983) deserves further research, because it has far-
reaching implications. Studies are needed to determine
whether psychiatric symptoms seen with AEDs in
patients with epilepsy are side effects with no prognostic
or clinical value, whether they are a necessary conse-
quence of seizure control, or whether they could be a
stage of a complex and progressive phenomenon leading
to a chronic psychiatric disorder (Mula et al., 2007). This
is an important distinction, and future research should
focus on clarifying the complex relationships between
seizures and aggressive behavior.
V. Antiepileptic Drugs and Aggression in Adult
Patients with Epilepsy
A. Introduction
We screened the literature for articles containing
references to AED treatment and aggression-related
behavior (aggression, agitation, anger, assault, homicide/
homicidality, hostility, impulsivity, irritability) and se-
lected relevant reports in epilepsy populations (see the
Supplemental Material for the search strategy and
evaluation). Supplemental Table 1 provides the full
listing of relevant studies retrieved for each AED and a
brief data summary. Relevant information from previous
systematic reviews of individual drugs or of AEDs as a
class has been includedwhere relevant.We also reviewed
product labels for information about aggression-related
behaviors, as an up-to-date source of relevant adverse
reactions in both clinical studies and postmarketing
experience (Table 3).
Our literature search and analysis captures only
formally reported events of aggressive behavior and
aims to identify large-scale, consistent patterns. As
clinicians, we all have anecdotal experience of aberrant
behaviors that appear in an individual patient after the
addition of an AED and resolve on its removal. We have
experienced this with all AEDs, including those that
have no formal reports of aggression. Every patient is an
individual, and each subtype of epilepsy is different;
although we have identified some broad trends, we
acknowledge that aberrant aggressive behavior may
develop in the occasional individual with an AED that is
not usually associated with such behavior. Additional
confounding factors that may result in incorrect attri-
bution of behavioral disturbance to a specific AED are
discussed elsewhere in this article and in previous
publications (Besag, 2001).
B. Review of Data for Each Antiepileptic Drug
The majority of studies we retrieved focused on one
AED. Those that included a number of AEDs are
discussed separately under each AED heading. One
study included sufficient patients and AEDs to allow
some comparisons of psychiatric side effects between
the AEDs and merits discussion here. A retrospective
chart review was conducted of adult outpatients seen
between 2000 and 2005 at a US epilepsy center and
included 1394 patients who had taken one of the follow-
ing newer AEDs (at the time): gabapentin, lamotrigine,
levetiracetam, topiramate, tiagabine, vigabatrin, and
zonisamide (Weintraub et al., 2007). Overall, an aver-
age of 8.4% of patients experienced AED-related
psychiatric/behavioral side effects. The highest rates
were seen with levetiracetam (16% incidence and 8%
discontinuations, significantly higher than average,
P, 0.001) and tiagabine (not significant, probably due
to low patient numbers); intermediate rates were seen
with topiramate and zonisamide and low rates were
seen with gabapentin (0.6% incidence, significantly
lower than average, P , 0.001), lamotrigine (4.8%
incidence, P , 0.001), and vigabatrin, felbamate, and
oxcarbazepine (not significant, probably due to low
patient numbers). A past psychiatric history was the
most significant predictor of AED-related behavioral/
psychiatric side effects (Weintraub et al., 2007).
1. Brivaracetam. Brivaracetam is included in this
article because it is currently under review for approval
as an adjunctive treatment of focal epilepsy with or
without secondary generalization. Our searches re-
trieved no published studies with brivaracetam that
included any of our key search terms. Manual searches
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TABLE 3
Summary of aggression-related behavior incidence and warnings, from AED labels
AEDs are listed in alphabetical order.
AED Aggression-Related AEs (and Incidence) Other Related Text, Warnings, or Precautions Epilepsy Specific? Source
Carbamazepine Aggression, agitation (rare: 0.01%–0.1%) “The possibility of activation of a latent
psychosis and, in elderly patients, of
confusion and agitation should be borne
in mind”
No Tegretol (2014a,b)
Clobazam “Aggressive behaviour towards self and
others may be precipitated”
No Frisium (2014),
Onfi (2014)
Irritability (7% with clobazam versus 5%
with placebo)
Yes (LGS) Onfi (2014)
Aggression (8% with clobazam versus 5%)
Aggression (1 of the 6 AEs leading to
clobazam discontinuation)
Clonazepam No incidence reported for aggression-
related AEs
“Clonazepam generally has a beneficial
effect on behaviour disturbances in
epileptic patients. In certain cases,
paradoxical effects such as
aggressiveness, excitability,
nervousness, hostility, anxiety, sleep
disturbances, nightmares, vivid
dreams, irritability, agitation,
psychotic disorders and activation of
new types of seizures may be
precipitated”
Yes Clonazepam
(2014)
No incidence reported for aggression-
related AEs
“Behaviour problems have been noted in
approximately 25% of patients”
Yes Klonopin (2013)
Eslicarbazepine Agitation, irritability (uncommon:
0.1%–1%)
Yes Zebinix (2014)
Ethosuximide Aggression, irritability (uncommon:
0.1%–1%), psychiatric AEs are seen
“particularly in patients who have
previously exhibited psychological
abnormalities”
Yes Zarontin (2012,
2014)
Felbamate Aggressive behavior, agitation (common:
$1%)
Yes Felbatol (2012)
Gabapentin Hostility (common: 1%–10%) Yes Neurontin
(2013a,b)In children, aggressive behavior is also
common (1%–10%)
Lacosamide Irritability (common: 1%–10%) Yes Vimpat (2014a,b)
Aggression, agitation (uncommon:
0.1%–1%)
Lamotrigine Aggression, irritability (common:
1%–10%)
No Lamictal (2014a)
Irritability (3% versus 2% with placebo,
adjunctive use)
Yes Lamictal (2014b)
Irritability (2%–5%, monotherapy)
Levetiracetam Hostility/aggression, nervousness/
irritability (common: 1%–10%)
Yes Keppra (2010)
Anger, agitation (uncommon: 0.1%–1%)
Behavioral AEs were more common in
children/adolescents than adults:
agitation (3.4%), aggression (8.2%),
irritability (11.7%, children aged ,4 yr)
Nonpsychotic behavioral symptoms
(levetiracetam versus placebo):
Warnings and precautions: “Behavioral
abnormalities including psychotic
symptoms, suicidal ideation,
irritability, and aggressive behavior
have been observed. Monitor patients
for psychiatric signs and symptoms”
Yes Keppra (2014)
Adults (13.3% versus 6.2%)
Pediatric (37.6% versus 18.6%)
Oxcarbazepine Agitation (1%–2% versus 1% with
placebo)
Yes Trileptal (2013,
2014)
Perampanel Adjunctive perampanel, occurrence in
epilepsy clinical trials: aggression,
anger, irritability (common: 1%–10%)
“Aggressive and hostile behaviour has
been reported in patients receiving
perampanel therapy. In perampanel-
Yes Fycompa (2015)
(continued )
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TABLE 3—Continued
AED Aggression-Related AEs (and Incidence) Other Related Text, Warnings, or Precautions Epilepsy Specific? Source
treated patients in clinical trials,
aggression, anger and irritability were
reported more frequently at higher
doses. Most of the reported events were
either mild or moderate and patients
recovered either spontaneously or with
dose adjustment. However, thoughts of
harming others, physical assault or
threatening behaviour were observed
in some patients (,1% in perampanel
clinical studies)”
Adjunctive perampanel, occurrence with
12 mg versus placebo in epilepsy
clinical trials:
“Serious or life-threatening psychiatric
and behavioral adverse reactions
including aggression, hostility,
irritability, anger, and homicidal
ideation and threats have been
reported in patients taking FYCOMPA.
These reactions occurred in patients
with and without prior psychiatric
history, prior aggressive behaviour, or
concomitant use of medications
associated with hostility and
aggression”
Yes Fycompa (2014)
Irritability: 12% versus 3%
Aggression: 3% versus 1%
Anger: 3% versus ,1%
Total incidence of hostility- and
aggression-related adverse reactions:
20% with 12 mg, 12% with 8 mg, 6%
with placebo
Phenobarbital AE rates are not given. The listing of
undesirable effects includes:
“paradoxical reaction (unusual
excitement)” and “behavioural
disturbances in children”
Yes Phenobarbital
(2013)
Phenytoin No mention of aggression-related
behavior in the SPC or USPI
Pregabalin Irritability (common: 1%–10%) No Lyrica (2014,
2015)Agitation, aggression, hostility
(uncommon: 0.1%–1%)
Retigabine Aggression-related behaviors reported
only in overdose
Yes Potiga (2013),
Trobalt (2014)
Rufinamide No aggression-related behaviors or
adverse reactions are listed in the SPC
Yes Inovelon (2013)
Aggression (3% versus 2% with placebo) Yes Banzel (2015)
Stiripentol Aggressiveness, irritability (common:
1%–10%)
Yes (children) Diacomit (2014)
Tiagabine Hostility (2%–5% versus 1%–2% with
placebo)
Yes Gabitril (2010,
2014)
Agitation (1% versus 0%)
Topiramate Irritability (.5%) Aggression was more common in children
than in adults
Mostlya Topamax (2013)
Aggression, agitation, anger, abnormal
behavior, irritability (common:
1%–10%)
Aggression, agitation (3% versus 2% with
placebo, clinical study in adults)
Yes (individual
epilepsy clinical
trial data)
Topamax (2014)
Aggression (2% versus 0% with placebo,
clinical study in adults)
Aggression (9% versus 4%, pediatric
trials)
Valproic acid Aggression, agitation (common: 1%–10%),
predominantly in children
Yes Epilim (2013)
No terms of interest are listed in the
epilepsy clinical study tables in the
USPI
Yes Depakene (2015)
Aggression, hostility, and irritability are
listed as adverse reactions reported in
postmarketing experience (no incidence
given)
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for brivaracetam randomized controlled trials (RCTs)
identified three phase III studies (Biton et al., 2014a;
Kwan et al., 2014; Ryvlin et al., 2014) and two phase IIb
studies (French et al., 2010; Van Paesschen et al., 2013)
that reportedAEs (Supplemental Table 1). Irritabilitywas
seen in approximately 5% of patientswith 50mg/d (versus
2%–4% with placebo) in three of the four studies (Van
Paesschen et al., 2013; Biton et al., 2014a; Ryvlin et al.,
2014). Discontinuation of brivaracetam was most often
prompted by psychiatric AEs (including aggression and
irritability) in two studies (Biton et al., 2014a; Ryvlin
et al., 2014). A post hoc meta-analysis across these phase
II/III studies reported that 6.8% of 1214 brivaracetam-
treated patients had nonpsychotic behavioral AEs, com-
pared with 4.2% in the placebo group (n = 425). This
incidence is lower than across the phase III studies with
levetiracetam [10.9% (n = 672) versus 4.8% with placebo
(n = 351)] (D’Souza et al., 2012).
2. Carbamazepine. One RCT with behavior-specific
measures was found. This study used a withdrawal
design to show that compared with the group that
continued AEDs, there was a small improvement in
depression and in “brooding” after withdrawal of AED
in seizure-free patients with epilepsy treated with
AEDs (both overall and in the carbamazepine subgroup)
(Hessen et al., 2007), suggesting that carbamazepine
may negatively affect mood. No measures directly
related to aggression (e.g., irritability, anger) were
reported. However, anecdotal experience of this re-
view’s authors suggests that carbamazepine may have
mood-stabilizing properties in some patients with
epilepsy; we have observed deterioration in mood after
withdrawal of carbamazepine.
No carbamazepine RCTs that reported aggression-
related behavioral AEs were retrieved by our searches.
Four observational studies were retrieved: two
showed slight evidence of aggression-related behaviors
with carbamazepine in patients with epilepsy (Shehata
et al., 2009; Wieshmann et al., 2011), one showed
positive behavioral effects (Pulliainen and Jokelainen,
1994), and one showed no behavioral worsening
(Friedman et al., 1992) (Supplemental Table 1). Using
the Liverpool Adverse Event Profile to assess patient-
reported AEs, one study reported that 16% of the 36
patients taking carbamazepine had feelings of anger
(compared with 33% for levetiracetam, 19% for val-
proic acid, and 15% for lamotrigine) (Wieshmann
et al., 2011). One study showed that patients with
epilepsy performed worse on several behavioral-
specific measures, compared with healthy controls,
and that behavior worsened in relation to dose and
duration of AED treatment (with carbamazepine or
valproic acid) (Shehata et al., 2009). A partially blinded,
prospective, observational study that focused mainly on
cognitive outcomes showed a slight improvement from
baseline in negative mood after 6 months of phenytoin or
carbamazepine (Pulliainen and Jokelainen, 1994). A
small observational study in patients with developmental
delay showed no increase in behavioral problems in
patients receiving carbamazepine as an AED only, but
worsening behavior was reported in patients receiv-
ing carbamazepine for either comorbid seizures and
TABLE 3—Continued
AED Aggression-Related AEs (and Incidence) Other Related Text, Warnings, or Precautions Epilepsy Specific? Source
Vigabatrin Pediatric: Agitation (very common:$10%) “Vigabatrin should be used with caution
in patients with a history of psychosis,
depression or behavioural problems.
Psychiatric events (e.g., agitation,
depression, abnormal thinking,
paranoid reactions) have been reported
during vigabatrin treatment. These
events occurred in patients with and
without a psychiatric history, and were
usually reversible when vigabatrin
doses were reduced or gradually
discontinued”
Yes (Sabril, 2014)
Adults: aggression, agitation, and
irritability (common: 1%–10%)
Adults: irritability (23% with 6000 mg
versus 7% with placebo)
Yes Sabril (2013)
Adolescents: aggression (5% versus 0%
with placebo)
Infantile spasm: irritability (16%–23%)
Zonisamide Adjunctive use: Yes Zonegran (2014)
Agitation, irritability (very common:
.10%)
Anger, aggression (uncommon, 0.1%–
1%)
Monotherapy:
Agitation (common: 1%–10%);
aggression (uncommon)
Adjunctive use: Yes Zonegran (2012)
Agitation/irritability (9% versus 4%
with placebo)
LGS, Lennox–Gastaut syndrome; SPC, summary of product characteristics; USPI, US prescribing information.
aPredominantly epilepsy studies, but a minority of studies in migraine prophylaxis.
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behavioral/psychiatric disorder or for psychiatric disor-
ders alone (Friedman et al., 1992).
3. Clobazam. No relevant studies in adult popula-
tions were retrieved.
4. Clonazepam. Our searches identified no RCTs for
clonazepam in adults, either using behavior-specific
endpoints or AE reporting.
One observational study (published in 1979) with
clonazepam in 40 patients aged 8–60 years with
generalized or focal seizures reported irritability as an
AE in 7 patients (17%) (Lander et al., 1979). Edwards
(1974) reported “irritability or aggressiveness” in 5%–
20% of patients in previous studies and “frank aggres-
siveness” requiring dose reduction in 20% of patients in
that author’s personal experience.
5. Eslicarbazepine Acetate. Our searches (including
abstracts at key epilepsy congresses; see the Supple-
mental Material) identified no RCTs or observational
studies that reported aggression-related data with
eslicarbazepine acetate in patients with epilepsy. One
conference abstract on the incidence of psychiatric AEs
with eslicarbazepine acetate did not mention any
aggression-related AEs (Biton et al., 2014b).
6. Ethosuximide. Our searches found no studies
reporting aggression-related behaviors in adults with
epilepsy treated with ethosuximide; however, psychosis
has been reported. For example, Fischer et al. (1965)
reported five episodes of psychosis in three adults
treated with ethosuximide; although no aggression
was reported in any of these cases, the patients were
described as being “tense.” The psychosis occurred in
clear time relation to the ethosuximide treatment; the
authors suggested that this might have been a mani-
festation of forced normalization.
7. Felbamate. Our searches identified no RCTs with
behavior-specific endpoints. Rates of psychiatric/
behavioral AEs were low with felbamate in the large
observational study discussed in section V.B (Weintraub
et al., 2007). One observational study of headache in 60
patients with epilepsy taking felbamate reported ad-
verse effects of “agitation or restlessness” in 14 patients
(23%), which caused discontinuation in 6 patients (12%)
(Ettinger et al., 1996). A case series of seven patients
with epilepsy with behavioral changes with add-on
felbamate reported that the changes included marked
agitation/irritability in four patients and that the
changes resolved on discontinuation in all seven patients
(McConnell et al., 1996) (Supplemental Table 1).
8. Gabapentin. Our searches identified no relevant
studies with gabapentin in adults with epilepsy, other
than the large observational study mentioned earlier
(section V.B); rates of psychiatric/behavioral AEs were
significantly lowerwith gabapentin (0.6% of 160 patients)
than the average (P , 0.001) (Weintraub et al., 2007).
9. Lacosamide. Our searches identified no relevant
studies with lacosamide in adults with epilepsy. A
manual search of lacosamide RCTs found no mention
of aggression-related behaviors as AEs in individual
epilepsy trials, in which the threshold for reporting AEs
ranged from $5% to $10%, in a pooled analysis of
lacosamide epilepsy trials (Sake et al., 2010) or in a
meta-analysis of AE data across 10 RCTs in epilepsy
and other indications (Zaccara et al., 2013).
10. Lamotrigine. Our searches identified one RCT
with behavior-specific endpoints. In adults with
focal seizures treated with adjunctive lamotrigine or
levetiracetam, anger and hostility improved (i.e., lessened)
from baseline with lamotrigine, with a significant differ-
ence versus levetiracetam, based on anger-hostility sub-
scale scores of the Profile of Mood States (POMS) scale
(Labiner et al., 2009).
Two observational studies designed to look at behav-
ior present good evidence that lamotrigine is not
typically associated with behavioral/aggressive side
effects. The large observational studymentioned earlier
(sectionV.B) reported that rates of psychiatric/behavioral
AEs were significantly lower with lamotrigine (4.8% of
547 patients, P , 0.001) than average (Weintraub et al.,
2007). Kato et al. (2011) used the Buss–Perry Aggression
Questionnaire and showed significant improvement from
baseline in aggression overall (and the anger subscale)
after 10 weeks of adjunctive lamotrigine in patients with
TLE. Other observational studies and case series are
detailed in Supplemental Table 1, and the results differ
among the different populations and comorbidities. In
general, lamotrigine has no detrimental effects with
respect to aggressive behavior, although there are some
reports of aggressive behaviors in patients with epilepsy
with intellectual disability (Ettinger et al., 1998). In this
population, the possibility of the “release phenomenon”
must be considered: releasing the individual from the
additional handicap of ongoing seizures can lead to
difficult behavior as his or her abilities improve (Besag,
2001). Lamotrigine may also have an alerting effect that
could lead individuals with intellectual disabilities to
becomemuchmore reactive to their environment. In both
eventualities, appropriate behavioral guidance can lead
to longer-term positive outcomes (Besag, 2001).
11. Levetiracetam.
a. Randomized Controlled Trials with Behavior-
Specific Endpoints. We identified only one RCT that
used a behavior-specific endpoint (the anger-hostility
subscale of the POMS) to explore aggression with
levetiracetam (Supplemental Table 1). This prospective
study by Labiner et al. (2009) showed that anger-
hostility subscale scores were significantly worse with
levetiracetam relative to lamotrigine, both after 20
weeks of add-on treatment and throughout the study.
Scores were worse than baseline with levetiracetam at
14 of the 20 weeks, whereas scores were improved at
every week with lamotrigine (significant differ-
ence versus levetiracetam at 12 of these weeks
and overall). One RCT of levetiracetam versus placebo
with a behavior-specific endpoint was conducted in
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adolescents and is reported in section VI.B.10 (de la
Loge et al., 2010).
b. Observational Studies with Behavior-Specific
Endpoints or Designed to Explore Aggression/
Behavior. Six observational studies exploredbehavioral
effects of levetiracetam using behavior-specific measures,
and three additional observational studies used
nonbehavior-specific endpoints (e.g., the Liverpool Ad-
verse Event Profile) with the defined intent to explore
adverse behavior or aggression (Supplemental Table 1).
In a prospective open-label study in 71 patients with
epilepsy, Lee et al. (2011b) saw significant improvement
from baseline in the Beck Anxiety Inventory after
adding levetiracetam and no significant changes in
most other measures and subscales (including a hostility
subscale). However, five patients (6.5%) discontinued
due to psychiatric symptoms (nervousness, irritability,
anxiety, hostility, depression, and suicidal ideation or
attempt) (Lee et al., 2011b).
In the large retrospective chart review already men-
tioned (Weintraub et al., 2007), levetiracetam had the
highest incidence of psychiatric/behavioral AEs (16%),
leading to discontinuations in 8% of 521 patients with
epilepsy taking levetiracetam. These rates were signif-
icantly higher than average (P , 0.001), and rates of
individual AEs (irritability, 9%; behavioral change, 3.5%)
were also significantly higher than average (P , 0.001).
In an interview-based study, which included carers as
well as patients, negative behavior change was reported
in 37% of 288 levetiracetam-treated patients and posi-
tive change was reported in 22%, whereas any behav-
ioral change was reported in only 9% of patients not
taking levetiracetam. Patient reports agreed with carer
reports of behavior change in most cases (85%). Aggres-
sion was the most prominent negative feature of the
symptom complex and clustered with increased energy
and improved concentration (Helmstaedter et al., 2008).
In a gene-association study based on these patients,
polymorphisms in three genes related to DA activity and
signaling were associated with negative psychotropic
AEs with levetiracetam, suggesting that reduced DA
activity may predispose patients with epilepsy to develop-
ing psychotropic AEs with levetiracetam (Helmstaedter
et al., 2013). The mechanisms underlying this associa-
tion are not yet understood (see also section IV).
In a very short-term study (1 week), no differences in
patient performance on several neuropsychological
tests and anxiety questionnaires were seen between
levetiracetam (n = 10) and pregabalin (n = 10) treatment.
Some improvements from baseline were seen with
levetiracetam (e.g., improved anxiety), but no aggression-
specific scales were used (Ciesielski et al., 2006).
In a prospective chart review of 517 patients with
various epilepsies treated with adjunctive levetiracetam,
10% developed psychiatric AEs, most commonly ag-
gressive behavior (3.5%). Risk factors were history of
febrile convulsions, previous psychiatric history, and
history of status epilepticus (Mula et al., 2003b). A
related study looked just at patients with epilepsy and
learning difficulties prescribed levetiracetam (N = 118);
the investigators reported that 15 patients (12.7%)
developed psychiatric AEs (most commonly aggression,
7.6%), and levetiracetam was discontinued in 7.6%
(Mula et al., 2004). Again, previous psychiatric history
was a risk factor for psychiatric AEs (Mula et al., 2004).
In a chart review of 108 patients with epilepsy treated
with both levetiracetam and topiramate (at different
times); overall, 13% and 30% had psychiatric AEs with
levetiracetam and topiramate, respectively (Mula et al.,
2007).
In a case-control study of 553 patients taking
levetiracetam, 7% of patients discontinued levetiracetam
due to behavioral abnormalities (most commonly depres-
sion and irritability) and 1.8% (n = 10) were considered a
danger to themselves or others (White et al., 2003).
In a study of patient-reported side effects with data
from the UK AED register, Wieshmann and Baker (2013)
found that 49% of 158 patients taking levetiracetam
reported anger as always or nearly always being a
problem, compared with 39% of 260 patients treated
with other AEDs and 7% of the 41 controls (people with
infrequent seizures and not taking AEDs) (Wieshmann
and Baker, 2013). This highlights the high rate of anger
when patients with epilepsy are asked the question
directly, as well as the higher rate with levetiracetam
than with other AEDs.
An earlier, smaller study by the same group using the
same registry reported that of 100 patients with
epilepsy taking AEDs, 33% of the 12 patients taking
levetiracetam said anger was always a problem, com-
pared with 19% of the 21 patients taking valproic acid,
16% of the 36 patients taking carbamazepine, and 15%
of the 20 patients taking lamotrigine (Wieshmann et al.,
2011).
A more recent observational study in 163 patients
taking levetiracetam reported aggressive behavior as
“always” a problem in 9.8% of the patients. These
patients also had a 7-fold increased risk of being
depressed, asmeasured with theNeurologic Depression
Disorders Inventory–Epilepsy (Mula et al., 2015).
c. Randomized Controlled Trials with Aggression
Data Extracted from Overall Adverse Event Reporting.
A recentmeta-analysis of 10 RCTs of add-on levetiracetam
provides some useful information, although it does not
capture all AEs across these studies (Mbizvo et al.,
2014). Each individual study reported only AEs occur-
ring in $5% ($10% in some studies) of patients, so any
AEs in the individual studies occurring below these
thresholds were excluded from the analysis entirely.
Hence, agitation was reported as an AE in one study in
children (6 of 101 versus 1 of 97 with placebo) and one
study in adults (3 of 28; 11% versus 0% with placebo),
and any agitation AEs below the reporting thresholds
in the other studies were ignored to give an overall
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incidence of agitation of 9 of 1092 (0.82% versus 0.14%
with placebo). Similarly, one study (in adults) reported
irritability as an AE (5 of 77; 6.5% versus 0% with
placebo), giving an overall incidence of irritability across
the meta-analysis of 0.46% (versus 0% with placebo).
Two earlier systematic reviews are more useful,
because they included all AE data from the levetirace-
tam database of adjunctive use in focal seizures (French
et al., 2001; Cramer et al., 2003). The review by French
et al. (2001) also includes healthy volunteers, elderly
patients with cognitive decline, and patients with anxi-
ety. French et al. (2001) reported a rate of behavioral AEs
of 13% in 769 patients treated with levetiracetam
(versus 6% with placebo) in placebo-controlled epilepsy
trials, 6.0% versus 4.1% in elderly patients in cognitive
studies, and 5.1% versus 5.5% in anxiety studies. Across
all of the levetiracetam epilepsy studies analyzed by
Cramer et al. (2003) (short-term placebo-controlled
trials and long-term open-label extensions), affective-
type behavioral AEs were seen in 25.4% of 1393
levetiracetam patients (versus 6.2% with placebo).
These included agitation (1.6% versus 0.2%), emotional
lability (3.0% versus 0.2%), hostility (3.3% versus 0.9%),
or nervousness (7.3% versus 1.8%) (Cramer et al., 2003).
Rates of behavioral AEs were lower in levetiracetam
trials in nonepilepsy indications, suggesting that pa-
tients with epilepsy are biologically more vulnerable to
behavioral/psychiatric AEs (French et al., 2001; Cramer
et al., 2003).
The individual levetiracetam RCTs are not discussed
here, and any RCTs we found that reported an
aggression-related AE are listed in Supplemental
Table 1.
d. Observational/Open-Label Studies with Aggres-
sion Data Extracted from Side-Effect Reporting.
Our searches retrieved eight such studies, which are
detailed in Supplemental Table 1. One large, long-term
study was comparative (N = 828), reporting discontin-
uation due to behavioral adverse effects in 19% of the
196 patients taking levetiracetam, compared with 2%–
7% with oxcarbazepine, lamotrigine, topiramate, and
zonisamide (Chung et al., 2007). In the other studies we
retrieved (see Supplemental Table 1), rates of individ-
ual behavioral AEs with levetiracetam ranged from 5%
to 24%, with the highest rate being the incidence of
irritability in a retrospective chart review of 568
patients treated with levetiracetam monotherapy/
polytherapy at a tertiary epilepsy center (Kang et al.,
2013). These studies generally approximated normal
clinical use of levetiracetam, although some excluded
patients with a history of serious psychiatric disorders
and some expressly included patients with a psychiatric
history or mental handicap. Discontinuation due to
aggression-related adverse effects was reported in
4.1%–10% of the overall populations in these studies
(4.1%–5.6%, if limited to studies with approximately
100 patients or more) and discontinuations due to
behavioral adverse effects in general were reported in
19% (Kang et al., 2013).
A number of case reports were retrieved, which in
general we have excluded from this review. However,
we selected one case series and one case study for a brief
mention, with all of the caveats that apply to interpret-
ing case reports.
Dinkelacker et al. (2003) described a case series of 33
patients with epilepsy who experienced aggressive
episodes during levetiracetam adjunctive therapy; the
authors estimated that 3.5% of all of their patients with
epilepsy experienced irritability or aggression attribut-
able to levetiracetam. In 24 of the 33 patients they
described, irritability was transient, none of the 24
patients had a history of unprovoked impulsive aggres-
sion, and 10 patients required dose reduction or discon-
tinuation of levetiracetam. In the remaining nine
patients (one woman, eight men), the aggressive symp-
toms were severe (including physical violence) and
necessitated emergency psychiatric treatment in two
cases. In four of these nine patients, there was a
history of irritability or aggression, and one patient
had experienced aggressiveness with gabapentin treat-
ment (Dinkelacker et al., 2003).
In a case study of a homicide during postictal
psychosis, in which the perpetrator had a complex
psychiatric and seizure history, the authors stated that
AED changes may have had a contributing role. Discon-
tinuation of carbamazepine 9 months before the homi-
cide may have “increased the propensity for postictal
mood dysregulation,” and the addition of levetiracetam
at the same time “may have increased impulsiveness”
(Eisenschenk et al., 2014).
12. Oxcarbazepine. Two relevant studies in adults
were retrieved. In the study by Weintraub et al. (2007)
mentioned previously, 5.6% of 162 oxcarbazepine-
treated patients had behavioral/psychiatric AEs,
slightly lower than the overall average, and no irrita-
bility was seen. In a retention study by Chung et al.
(2007), only 2 of 97 patients discontinued oxcarbaze-
pine due to behavioral AEs, the lowest rate of all of the
AEDs that were included.
13. Perampanel. Our searches retrieved one of the
three perampanel phase III RCTs in epilepsy, the open-
label extension, a meta-analysis of all perampanel
double-blind RCTs (epilepsy and other indications), an
observational study, and a case study. By searching
reference lists (excluding duplicates, data that had pre-
viously been published, or extension studies that had
been superseded by more recent follow-up) and recent
conferences (and excluding conference abstracts that had
since been published in full), we ultimately retrieved 27
relevant articles (see Supplemental Table 1 and below).
a. Randomized Controlled Trials with Behavior-
Specific Endpoints. We found no studies in adults with
behavior-specific endpoints (see section VI.B.12 for a
perampanel study in adolescents with behavior-specific
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assessments). Post hoc analyses specifically designed to
explore aggression in perampanel RCTs are reported
later in this section.
b. Observational Studies with Behavior-Specific
Endpoints or Designed to Explore Aggression/Behavior.
We found no observational studies in adults with behavior-
specific endpoints.
c. Randomized Controlled Trials with Aggression
Data Extracted from Overall Adverse Event Reporting.
Of the five perampanel RCTs in epilepsy (three phase
III, two phase II), two reported aggression-related AEs
(French et al., 2012, 2013), whereas one phase III study
and the two phase II studies did not (Krauss et al.,
2012). A pooled analysis of all data from the phase III
trials showed that 30 of the 225 patients taking 12 mg
perampanel (11.8%) reported irritability as an AE
(versus 2.9% with placebo and 3.9%–6.7% with 2–8 mg
perampanel), and aggression as an AE in 3% of patients
taking 12 mg perampanel (versus 1% with placebo, 1%
with 4 mg, and 2% with 8 mg). No other aggression-
related AEs occurred in $5% of patients in any
treatment group (Steinhoff et al., 2013). Serious psy-
chiatric AEs were seen in 12 patients (1.2%) taking
12 mg perampanel (versus 0.9% with placebo), with
aggression being the most common (3 of 1038 patients
taking perampanel or 0.29% versus none with placebo).
Because of the interest in aggressive behavior with AEs,
a further analysis was conducted in the pooled phase III
clinical trial population, using both broad and narrow
SMQs for events suggestive of hostility or aggression.
The broad SMQ identified events broadly suggestive of
hostility or aggression (e.g., including events like lacer-
ation, regardless of cause) in 6% of placebo-treated
patients and in 5% (4 mg), 12% (8 mg), and 20%
(12 mg) of perampanel-treated patients (Steinhoff et al.,
2013). Homicidal ideation and/or threat were exhibited in
0.1% of 4368 perampanel-treated patients in controlled
and open-label studies, including nonepilepsy studies
(Steinhoff et al., 2014a). A population pharmacokinetic–
pharmacodynamic study using the pooled phase III
epilepsy population confirmed a significant association
betweenperampanel plasma concentration and incidence
of aggression (Gidal et al., 2013). A meta-analysis of nine
RCTs including studies in Parkinson disease (Zaccara
et al., 2013) reported on 3947 patients, 2627 of whom had
been randomized to perampanel. In this analysis, similar
terms were merged (e.g., irritability and aggression). No
AEs were significantly associated with dosages of 2 or
4 mg/d, and the only behavioral AE significantly associ-
ated with any dosage of perampanel was irritability
(which included aggression) with 12 mg/d perampanel.
Several post hoc analyses of the perampanel epilepsy
and nonepilepsy clinical trial databases have been
conducted; aggressive/irritable behavior was seen only
in epilepsy populations (Ettinger et al., 2014; LoPresti
et al., 2014), and the incidence was not significantly
different in patients taking concomitant levetiracetam
(versus no concomitant levetiracetam) (Fain et al., 2015)
(see Supplemental Table 1 for details of these analyses).
After our searches were completed, these conference
abstracts were recently published as a full article
(Ettinger et al., 2015).
The most recent analysis of the open-label extension
study to the phase III trials, which followed patients for
a median of 1.5 years, reported irritability in 11.5% and
aggression in 5.1% of patients over the entire exposure
period (N = 1216). Overall, 3.9% of patients had $1
psychiatric serious AE. Among these were 2 serious AEs
of agitation (0.2%) and abnormal behavior (0.2%) and 12
serious AEs of aggression (1.0%). Aggression resolved in
five patients while they continued perampanel, and
seven patients discontinued (Krauss et al., 2014).
Irritability and aggression led to the discontinuation
of perampanel in 1.3% and 0.4% of patients, respectively.
The recently completed phase III study of perampa-
nel in patients with primary generalized tonic–clonic
seizures reported irritability as the only individual AE
with an incidence of $5% (11.1% of 81 patients with
perampanel versus 3.7% of 81 patients with placebo).
The combined incidence of hostility- or aggression-
related AEs (as per the broad and narrow SMQ terms)
was 18.5% with perampanel versus 4.9% with placebo;
using just narrow SMQ terms (i.e., AEs very likely to be
related to aggression or hostility), the rates were 2.5%
with perampanel and 0% with placebo (French et al.,
2015).
d. Observational/Open-Label Studies with Aggres-
sion Data Extracted from Side-Effect Reporting.
We identified two published observational studies. In
one (a prospective, multicenter clinical audit of adjunc-
tive perampanel in 281 patients with refractory epi-
lepsy), low rates of aggression (2.8%) and irritability
(2.1%) were reported (Steinhoff et al., 2014b). In the
other (a single-center case series of 47 patients), the
median dose taken by patients was 8 mg. The most
common AEs requiring withdrawal of perampanel were
behavioral: aggressive behavior in two cases (4.3%),
suicidal ideation in two cases (4.3%), and aggressive
behavior together with suicidal ideation in one further
patient (2.1%) (Coyle et al., 2014). Another 11 observa-
tional studies (N = 16–111) were reported in conference
abstracts, with populations ranging from institutional-
ized adults with highly refractory epilepsy to less severe
patients in general neurology practice (see Supplemen-
tal Table 1). Aggression, irritability, and/or behavioral
disturbance were reported as AEs in most (but not all)
abstracts, ranging in incidence in those reports from 8%
to 36% (Supplemental Table 1).
e. Case Studies. In a patient with moderate in-
tellectual disability, a history of challenging behavior,
and severely refractory epilepsy, the addition of per-
ampanel 8 mg significantly improved seizure frequency
and duration but worsened aggressive behavior and
resulted in the patient being unable to live at home,
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despite reducing the perampanel dose and the addition
of antipsychotics (Dolton and Choudry, 2014).
14. Phenobarbital. Our searches retrieved only one
relevant study with phenobarbital (Hanzel et al.,
1992). The authors of this case report suggested that
phenobarbital may cause behavioral AEs or exacerbate
maladaptive behaviors, whichmaymask or suppress the
effectiveness of neuroleptics (in this case, chlorproma-
zine) in treating aggressive behavior in patients with
seizures and comorbidities (Hanzel et al., 1992). We also
considered data in healthy patients. In 49 healthy adults
who underwent a battery of neuropsychological tests,
scores in the anger subscale of the POMS were
significantly worse (increased anger) than baseline
after 1 month taking 15 mg/d phenobarbital, but not
with phenytoin (30–100 mg/d) or valproate (250 mg/d)
(Meador et al., 1995).
15. Phenytoin. Only one relevant study with phe-
nytoin was retrieved. In this observational study in 43
newly diagnosed patients with epilepsy, a small de-
crease in irritability (assessed with the POMS scale)
was seen after phenytoin treatment was commenced
(Pulliainen and Jokelainen, 1994).
16. Pregabalin. One study with pregabalin specifi-
cally investigated the neuropsychological and psychiat-
ric effect of pregabalin and levetiracetam in 20 patients
with epilepsy but only over the course of 1 week of
treatment, so the results have very limited utility. No
major neuropsychiatric effects were seen (Ciesielski
et al., 2006). Two observational studies in refractory
epilepsy, one in inpatients with intellectual disability
and one in outpatients, showed infrequent behavior-
related AEs (Huber et al., 2008; Valentin et al., 2009)
(Supplemental Table 1).
17. Retigabine. Our searches revealed no relevant
retigabine studies in adults. Neither the pivotal trial
publications nor a pooled analysis of these three trials
reported any aggressive or behavioral AEs above the 5%
(10% in one case) reporting thresholds (Porter et al.,
2007, 2012; Brodie et al., 2010; French et al., 2011).
Searches of epilepsy congress abstracts for retigabine
revealed no further relevant data.
18. Stiripentol. Only one relevant study was re-
trieved, which was an observational study in Japanese
adults and children with Dravet syndrome (Inoue et al.,
2009). Irritability was observed in three of the eight
patients aged $13 years in the early and intermediate
period but resolved, and no adults discontinued due to
irritability.
19. Tiagabine. We retrieved two observational stud-
ies that examined behavior with tiagabine. The largest
was the observational study by Weintraub et al. (2007),
which showed high rates of psychiatric/behavioral AEs
(15.8% with tiagabine versus 8.4% average), and irrita-
bility (10.5%), depression (5.3%), anxiety (5.3%), and
psychosis (5.3%) with tiagabine; however, the data are
based on only 19 patients. A small controlled study used
a mood and behavior rating scale and found no signif-
icant effect of tiagabine on these scores (Sveinbjorns-
dottir et al., 1994). Adverse event reporting from this
study showed that 3 of the 19 patients withdrew early
due to aggression; aggression/irritability was reported
in 3 of 11 patients taking tiagabine in the double-blind
portion of the study versus 0 of the 11 patients in the
placebo period (Sveinbjornsdottir et al., 1994). The only
other relevant publication was a report of two cases in
which the addition of tiagabine controlled postencepha-
litic seizures and improved behavior (including aggressive
outbursts) (Kaufman et al., 2002).
20. Topiramate. We retrieved no RCTs and four
observational studies that focused on behavior/aggression,
as well as five observational studies from which behavior/
aggression rates can be extracted from side-effect report-
ing (Supplemental Table 1). In their observational
study, Weintraub et al. (2007) concluded that top-
iramate (n = 112) had intermediate rates (6.3%
overall) of psychiatric/behavioral AEs compared with
other AEDs. In a retrospective analysis, Mula et al.
(2003a) reported psychiatric AEs in 24% of the 431
patients assessed, with aggressive behavior in 5.6%.
In a chart review of 108 patients with epilepsy treated
with both levetiracetam and topiramate (at different
times), overall 13% and 30% had psychiatric AEs with
levetiracetam and topiramate, respectively (Mula
et al., 2007). A case series, which explored in detail
103 patients who developed psychiatric AEs with
topiramate, found that nearly one-half of the sample
had affective disorder, with aggressive behavior being
the next most common (23%). The aggression resolved
in the majority of patients with discontinuation (or
reduction) of topiramate (Mula and Trimble, 2003).
Aggressive behavior was associated with seizure wors-
ening, suggesting that it was a direct expression of the
epileptic state (ictal, preictal, or postictal; see earlier).
In a retention rate study by Chung et al. (2007),
topiramate had the lowest retention rate (44.2%), but
few of the discontinuations were due to behavioral AEs
(5 of 156 patients). In the other observational studies we
retrieved, irritability was reported in a wide range of
patients, from ,1% up to 20%, and discontinuation due
to irritability/aggression/agitation was reported in 5%–
12% (see Supplemental Table 1 for details) (Tartara
et al., 1996; Stephen et al., 2000; Bootsma et al., 2004;
Voronkova et al., 2007).
21. Valproic Acid. We identified one prospective,
controlled study in adults that used aggression-specific
endpoints and we also identified one small observa-
tional study (Supplemental Table 1). In a prospective
study using cognitive and behavioral endpoints, both
treated (seizure-free) and untreated (newly diagnosed or
never-treated) patients with epilepsy had worse aggres-
sion (total and verbal) compared with healthy controls,
and total aggression scores were worse in patients
treated with valproic acid comparedwith carbamazepine
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(Shehata et al., 2009). In a small observational study (N=
55) conducted in 1978, aggressive behavior was seen in
one patient (Ruuskanen et al., 1979).
22. Vigabatrin. Our searches identified one individ-
ual RCT with vigabatrin that reported behavior-related
AEs (Loiseau et al., 1986), as well as one pooled analysis
across all vigabatrin trials (randomized, double-blind,
placebo-controlled studies of add-on vigabatrin) that
aimed to explore psychiatricAEs (LevinsonandDevinsky,
1999). The small (n = 23) crossover study reported
irritability as an AE in two patients during the placebo
phase and one patient during the vigabatrin phase
(Loiseau et al., 1986), and the pooled analysis showed
an odds ratio of . 1 for incidence of aggressive reaction
and for agitation, but this was small and not significant
(Levinson and Devinsky, 1999). Wemanually identified a
Cochrane review of vigabatrin clinical trial data up to
October 2012 (N = 747), and this meta-analysis did not
report any behavioral events significantly associated with
vigabatrin (Hemming et al., 2013). Therefore, we did not
extend our manual searches any further to evaluate any
individual vigabatrin clinical studies.
We identified one small observational study in adults
with refractory epilepsy and severe learning difficulties.
Of 22 patients treated with add-on vigabatrin, aggres-
sion and agitation were reported in 4 (18%) and 2 (9%),
respectively (Armour et al., 1992).
Behavioral disturbances and aggression were report-
edwith vigabatrin in a number of case reports soon after
its approval (e.g., in 7 of 145 patients in one letter to the
editor in the Lancet, and 9 of 119 patients in another
letter) and the outbursts were occasionally extreme
and violent (Robinson et al., 1990). A follow-up of 136
patients in whom behavioral problems were reported
with vigabatrin to either the authors or the manufac-
turers found sufficient detail for 81 of these patients,
depression in 22 patients, and psychosis in 28 patients.
There was no mention of aggression-related behaviors
in this report (Thomas et al., 1996). A study of cognitive
and behavioral effects in healthy volunteers found no
effects of vigabatrin on cognition or mood/behavior,
although this was only with short-term use (Thomas
and Trimble, 1996).
23. Zonisamide. Our searches retrieved no studies
that used aggression- or behavior-related endpoints,
but one RCT and one meta-analysis reported aggression-
related AEs (Sackellares et al., 2004; Carmichael et al.,
2013), and two observational studies reportedaggression-
related AEs (Chung et al., 2007; Weintraub et al., 2007),
one of which was specifically designed to explore
psychiatric/behavioral effects of AEDs (Supplemental
Table 1).
The recent meta-analysis of zonisamide studies (stud-
ies published up to February 2013) found a significant
association between zonisamide and agitation/irritability
(relative effect versus placebo 3.25; 95% confidence in-
terval, 1.05–5.27). The individual study retrieved by our
searches (Sackellares et al., 2004) was included in this
meta-analysis, so it is not discussed separately here. The
observational studieswe retrieved have been discussed
earlier in this review. Weintraub et al. (2007) con-
cluded that zonisamide (n = 192) had an intermediate
rate of psychiatric/behavioral AEs (9% versus 8.4%
average), and Chung et al. (2007) reported few discon-
tinuations due to behavioral AEs with zonisamide
(9.8% of 128 patients versus 19% of 196 patients with
levetiracetam).
C. Conclusions
A previous review of the psychotropic effects of AEDs
concluded that “There is a need for large-scale, pro-
spective, randomised, double-blind, placebo-controlled
studies that are properly designed to assess psychotro-
pic effects of AEDs so as to control for confounding
factors” (Piedad et al., 2012). Our review of the data,
focusing just on aggression-related behaviors, must
come to a similar conclusion: that few well-designed
and reliable studies have been performed. Although it
did not use behavior-specific assessments and does not
include all currently available AEDs, the comparative,
observational study by Weintraub et al. (2007) gives
perhaps the most useful information. This study found
levetiracetam to have the highest rates of behavioral
AEs, and gabapentin to have the lowest (Weintraub
et al., 2007).
Information from regulatory drug trials should be
treated with caution, because the majority do not
include behavior-specific endpoints and interpreting
AE reporting across the spectrum of aggression-
related behaviors is fraught with difficulties. More
information is available on the newer AEDs because
with each new approval, scrutiny of psychotropic side
effects is increasing; however, equivalent scrutiny is
often not possible for older AEDs because the questions
were not asked of their regulatory trial data. Another
gap in the literature is in regard to the relationship
between AEs (e.g., aggression) and efficacy. Reports
suggest that AEDs may have different side effects when
the drug is effective (i.e., patients enter remission) and
when treatment fails to deliver seizure freedom (Shih
and Ochoa, 2009), but none of the studies we reviewed
included any information on the relationship between
antiseizure effects and aggressive behaviors. This re-
lationship is further complicated by the fact that un-
controlled epilepsymay impair behavior in similar ways
to the side effects of AEDs (Baker and Marson, 2001).
Based on available data, levetiracetam, perampanel,
and topiramate seem to be associated with increased
rates of irritability, hostility, and/or aggression, partic-
ularly in patients with a previous history of psychiatric
symptoms. For such patients, these drugs should be
usedwith caution. Product labels are generally consistent
with this conclusion and provide a useful benchmark.
From US labels, 13% of adults taking levetiracetam
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(pooled, all doses) have nonpsychotic behavioral symp-
toms, 12% of patients taking 8 mg perampanel have
hostility/aggression-related AEs (20% with 12 mg), and
2%–10% of adults taking topiramate have aggression-
related AEs (Table 3).
There are mixed data for vigabatrin, valproic acid,
and zonisamide. Early vigabatrin case reports of some-
times violent aggressive behavior are not supported by
evidence of increased rates in pooled analyses, although
very high rates of irritability (23%) are reported in the
vigabatrin US label (Sabril, 2013). One controlled study
with valproic acid showed significantly worse aggres-
sion than with carbamazepine, but we found no other
data supporting a risk of aggressive effects. Data from
zonisamide clinical studies show an increased rate of
agitation/irritability versus placebo but low rates in
observational studies and no evidence for aggression in
studies using behavior-specific measures.
There are reasonable data supporting no specific risk
of aggression-related behavior with carbamazepine,
eslicarbazepine acetate, gabapentin, lamotrigine,
oxcarbazepine, and retigabine.
There are insufficient data for any conclusions for
clobazam, clonazepam (although the clonazepam US
label reports behavior problems in approximately 25%
of patients with epilepsy; Klonopin, 2013), ethosuximide,
felbamate, gabapentin, phenobarbital, phenytoin,
pregabalin, and tiagabine. Because the developmental
AED brivaracetam has only been used in clinical trial
populations to date, there is insufficient available
evidence, although the incidence of nonpsychotic be-
havioral AEs appears to be approximately 7% (D’Souza
et al., 2012).
VI. Aggression with Antiepileptic Drugs in
Children and Teenagers with Epilepsy
A. Introduction
The most striking aspect of the literature search in
this area is, once again, the lack of high-quality data.
There are almost no blinded, controlled studies using
accepted measures of behavioral disturbance or pro-
viding adequate information either on the nature of the
aggressive behavior itself or on factors that would allow
a reasonable evaluation of causation. As stated earlier,
a more comprehensive discussion of the confounding
factors that could lead to false attribution of behavioral
disturbance to a specific AED has been published
elsewhere (Besag, 2001). The lack of data is surprising,
considering the size of the problem. A questionnaire
survey by Brown (1994) showed that 60% of the 896
children and teenagers surveyed felt that their antiepi-
leptic medication caused tiredness and .50% viewed it
as being responsible for poor concentration. Approxi-
mately 50% reported that that theywere “cross/irritable”
and about 30% reported being “angry” as a result of the
medication (Brown, 1994). Although this survey was
conducted in a highly selected population (namely,
members of the British Epilepsy Association) and lacked
a control group, the results are striking and highlight the
need for attention to aggressive adverse effects of AEDs.
B. Review of Data for Each Antiepileptic Drug
The evidence for aggression associated with each of
the AEDs (in alphabetical order) is presented. In
general, data in very young infants (e.g., those with
infantile spasms) are not included, because AEs of
irritability in these babies cannot be interpreted as
aggressive behaviors; however, the data are reported
(with caveats) where infants formed part of a larger
population that cannot be separated.
1. Acetazolamide. No evidence was found.
2. Carbamazepine. No evidence was found.
3. Clobazam. We identified one double-blind, ran-
domized trial with clobazam that included behavior-
specific measures (Paolicchi et al., 2015). Using data
from a trial of clobazam to treat Lennox–Gastaut
syndrome, Paolicchi et al. (2015) carried out a post hoc
analysis of all randomized pediatric patients (aged
#18 years) treated with at least one dose of study drug
or placebo. Of the 146 clobazam-treated patients,
aggression-related AEs were seen in 23 (15.8%), com-
pared with 8.3% of placebo patients. In patients taking
high- andmedium-dose clobazam,most of the aggression-
related AEs occurred during the 3-week titration period,
whereas they were evenly distributed in the low-dose
and placebo groups during the 15-week study. The
aggression-related AEs included the following MedDRA-
preferred terms: aggression, irritability, abnormal be-
havior, perseveration, and negativism (although no
patients fell into the perseveration category and only
one fell into the negativism category). Three patients
discontinued clobazam because of aggression-related
AEs. There was no significant difference between
clobazam and placebo in the behavior item scores on
the Achenbach Child Behavior Checklist (CBCL),
although there was a trend toward worsening scores
in the aggression domain with clobazam in patients
with a history of aggressive behavior (Supplemental
Table 2). The authors concluded that the overall rate of
aggression was low with clobazam, was dose depen-
dent, resolved by study end, and was independent
of the history of aggression/behavioral problems
(Paolicchi et al., 2015). The other clobazam studies
we retrieved did not use behavior-specific measures
but reported behavior-related AEs in varying degrees
of detail (Supplemental Table 2). In a small, random-
ized, blinded (double dummy) study, Bawden et al.
(1999) compared 24 patients taking clobazam with 17
receiving standard monotherapy (9 received carbama-
zepine and 8 received phenytoin). Three of the patients
taking clobazam exhibited externalizing behavioral
AEs, compared with three who received standard mono-
therapy; three taking clobazam exhibited internalizing
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behavioral AEs, compared with two taking standard
monotherapy (Bawden et al., 1999). The rate of behav-
ioral AEs was very similar between the two groups but
it is difficult to draw any conclusions from such small
numbers. Sheth et al. (1994, 1995) reported that 7 of 63
children (11%) treated with clobazam for refractory
epilepsy developed severe behavioral disturbance.
“Aggressive agitation” was reported in the seven chil-
dren (mean age 6.4 years). The aggression was de-
scribed by parents as being “animal-like” and included
biting, kicking, head-banging, tantrums, and hyperac-
tivity, all of which were said to be out of character
(Sheth et al., 1994, 1995).
Jan and Shaabat (2000) reported a small, open,
uncontrolled study of 31 children with refractory epi-
lepsy, aged 2months to 15 years, in whom clobazamwas
added to the existing antiepileptic medication in dos-
ages of up to 2 mg/kg per day. Seven of the 31 children
had adverse effects, including behavioral change in two
(Jan and Shaabat, 2000). The clobazam had to be
withdrawn in three children because of repeated vomit-
ing or behavioral changes but it was not clear, from the
report, whether it had to be withdrawn in both of the
children with the behavioral change.
Klehm et al. (2014) reported a large retrospective
chart review in 300 children (mean age 9.1 years) with
refractory epilepsy who were prescribed clobazam. The
children had a variety of seizure types (many had
multiple seizure types), and the majority of patients
(97%) were taking at least one other AED. The median
starting dosage was 0.2 mg/kg per day and the average
dosage at last follow-up was 0.73 mg/kg per day (range,
0.05–3.3 mg/kg per day). The median seizure reduction
was 80%; the 50% responder rate was 67.7% and 84
patients (28%) were seizure free at the last follow-up.
Twenty-three patients (7.7%) were reported as having
AEs related to mood or behavior change (Klehm et al.,
2014).
4. Clonazepam. None of the clonazepam studies
used behavior-specific measures; two observational
studies and two reviews of previous studies were included
(Supplemental Table 2).Mikkelsen et al. (1976) carried out
a single-blind, placebo-controlled trial of clonazepam in 10
patientswith simple absence seizures and10patientswith
myoclonic-atonic seizures. Most of the patients (17 of 20)
were aged ,18 years. Clonazepam had to be withdrawn
from two of the patients because of severe irritability,
dysphoria, and aggressiveness in one case and somno-
lence, behavioral disturbance, and lack of efficacy in the
second case. Further details were sparse in this report.
Lander et al. (1979) reported that 22 of 40 patients
treated with clonazepam for refractory epilepsy had
“undesirable effects” attributable to the clonazepam,
the commonest of which were drowsiness, loss of
concentration, irritability, and aggression.
Kalachnik et al. (2002) reviewed behavioral ad-
verse effects of benzodiazepines, including clonazepam,
diazepam, and lorazepam, commenting that these are
easily overlooked and under-recognized. They stated
that behavioral adverse effects occurred in 13% of 446
individuals with mental retardation prescribed these
AEDs for behavioral, psychiatric, or medical conditions.
The rate of behavioral disturbance in the 208 individ-
uals who had epilepsy was 15.4%.
In a review of clinical trials of clonazepam, Browne
(1976) commented that behavioral disturbance occurred
in a minority of patients, usually children. This repre-
sented an exacerbation of the previous disorder in some
cases, but not in others. The behaviors were variously
described as irritable, aggressive, excitable, irrational,
antisocial, temperamental, violent, disobedient, noisy,
and hard to discipline. In 10 studies, the percentage of
behavioral disturbance ranged from 2% to 50% (median
17%). The behavioral disturbance sometimes resolved
with a reduction in dosage but required discontinuation
of the clonazepam in other cases.
5. Eslicarbazepine Acetate. In a prospective, open-
label study of 29 children aged between 2 and 17 years,
aggressive behavior was reported in one child and one
other child had “aggression aggravated” (Almeida et al.,
2008).
6. Ethosuximide. The only evidence retrieved for
ethosuximide was two case studies. Yamamoto et al.
(2001) reported that an 11-year-old boy with refractory
myoclonic epilepsy and severe psychomotor delay had
complete control of myoclonic seizures with ethosuximide
but had “behavioural changes, more of the manic type.”
This was attributed to the forced normalization phe-
nomenon because the EEGwas said to be almost normal
during the episode (Yamamoto et al., 2001).
A case study by Chien (2011) described a 10-year-old
boy who developed acute mania with psychotic symp-
toms and suicidal ideation with ethosuximide.
7. Gabapentin. Two observational studies that re-
ported aggression from AE data and two case studies
were identified (Supplemental Table 2). Khurana et al.
(1996) carried out a chart review of 32 children treated
with gabapentin. Behavioral AEs occurred in 15 pa-
tients. Physician intervention was required in four
children: one became more withdrawn and the other
three became more hyperactive and more aggressive
with violent outbursts andmood swings (Khurana et al.,
1996). In three of the four children, the behaviors
returned to baseline after the gabapentin was stopped.
Lee et al. (1996) reported on seven children who
developed behavioral adverse effects in association with
gabapentin. It is not clear how these children were
selected from the larger pool of 55 children treated at this
center (Lee et al., 1996). In some cases, the behaviors
were present before treatment but were exacerbated
when the child was treated with gabapentin. New
behaviors included oppositional defiant disorder (58%)
and conduct disorder (33%). Again, because of the small
numbers, it is difficult to draw any firm conclusions.
Epilepsy, Antiepileptic Drugs, and Aggression 589
The results of studies carried out by one of the current
authors and his colleagues on 14 teenagers, using a
standard instrument for monitoring behavior (the Rut-
ter Behavioral Scales) before and during treatmentwith
gabapentin, did not confirm these results. There were
no significant behavioral changes with gabapentin: two
subjects moved from the “nondisturbed” to the “dis-
turbed” behavioral range and one moved from the
disturbed to the nondisturbed range. In a further
behavioral study on the same pool of patients, 6 female
and 10male subjects were matched for sex as well as for
age and other parameters (as closely as possible).
Examination of the changes in the Rutter scale scores
revealed no significant differences between the
gabapentin-treated group and the comparison group
(Besag, 1996).
A case study by Tallian et al. (1996) reported two
children who had aggressive behavior with gabapentin.
The first case was a 16-year-old boy in whom the
seizures were fully controlled but his appetite decreased
and he had problems sleeping. He then developed
aggressive behavior with biting, slapping, scratching,
growling, and “acting like an animal.” The gabapentin
was discontinued and the behavioral disturbance re-
solved. When the gabapentin was recommenced and the
dose increased, the aggression became marked. When
the gabapentin was subsequently discontinued, the
problem resolved again. The second patient was a
6-year-old girl with intellectual disability and ADHD
but no history of aggressive behavior. When gabapentin
was commenced, she stopped interacting socially; she
became physically aggressive when confronted socially
and she assaulted other children. A moderate improve-
ment in behavior occurred when the gabapentin dose
was decreased; it was continued because her parents
judged her behavior as being tolerable and she remained
seizure free.
A case series described by Wolf et al. (1995) reported
behavioral problems in three children with learning
disability when treated with gabapentin. The behaviors
described included unprovoked outbursts of anger in
case one, episodes of hyperactivity and oppositional
behavior in case two, and outbursts characterized by
throwing food, screaming, and fighting in case three.
It is difficult to assess the causative role of the
gabapentin itself in all of these reports, not only because
of the small numbers and open nature of the studies but
also because of confounding factors such as drug
interactions and changes in seizure control.
8. Lacosamide. Our searches for lacosamide data in
children retrieved only small observational studies
(Supplemental Table 2).
Gavatha et al. (2011) reported a study in 18 children
(10 male and 8 female, aged 3–18 years) with intellec-
tual disability. No aggression was specifically reported
but there were two cases of irritability. No further
details were provided (Gavatha et al., 2011).
Guilhoto et al. (2011) analyzed results from a retro-
spective study of 16 young people with treatment-
resistant epilepsy (7 male and 9 female, aged 8–21
years, mean age 14.9 years). Lacosamide was with-
drawn in one boy (aged 8.4 years) because of severe
behavioral outbursts (Guilhoto et al., 2011).
Heyman et al. (2012) carried out a retrospective study
of medical records of 17 children (10 male and 7 female,
aged 1.5–16 years, mean age 8 years) with epilepsy
taking lacosamide. Restlessness was reported in two
patients but no other behavioral disturbance was re-
ported (Heyman et al., 2012).
Kim et al. (2014) described a retrospective study of
medical records that included 21 children (16 male and
5 female, aged 1.2–17.9 years, median age 13.9), 2 of
whom discontinued lacosamide because of AEs (aggres-
sive behavior and depression).
9. Lamotrigine. Two observational studies were re-
trieved (Supplemental Table 2). In a long-term, open-
label extension study, Piña-Garza et al. (2008) followed
204 infants (aged 1–24 months), treated with lamotri-
gine after phase III studies. The only AE that they
considered could be reasonably attributable to lamotri-
gine in.2% of patients was irritability, which occurred
in 10 patients (5%) (Piña-Garza et al., 2008).
Cardenas et al. (2010) carried out a retrospective
review of patients who developed “neurobehavioural
adverse reactions to lamotrigine.” They identified nine
children (seven male and two female, mean age 5 years)
who became hyperactive and agitated, over a wide
range of doses from 0.7 to 14 mg/kg per day. Five
patients developed self-injurious and violent behaviors,
two had severe insomnia, and the most affected patient
(a 6-year-old boy) developed “extremely volatile mood
and affect” with visual and auditory hallucinations
together with insomnia. All nine patients improved
markedly after discontinuation or dose reduction of the
lamotrigine. These authors said that severe, reversible
neurobehavioral disturbance associated with lamotri-
gine therapy had not previously been reported in the
literature.
It should be noted that lamotrigine is now widely
acknowledged as an AED that can improve mood
significantly; large studies have established this in
adults and the positive psychotropic effects of improving
mood/behavior in young people with or without epilepsy
have also been confirmed (Frye et al., 2000; Cramer
et al., 2004; Biederman et al., 2010).
10. Levetiracetam. There are several reports of
aggression in children with epilepsy treated with
levetiracetam, including two RCTs with behavior-
specific measures; however, there are also several
reports of improved behavior (Supplemental Table 2).
Our searches identified one study that specifically
explored the behavioral effects of levetiracetam in a
randomized, placebo-controlled study, using standard-
ized measures including the CBCL and the Child
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Health Questionnaire–Parent Form 50 (de la Loge
et al., 2010). Patients received adjunctive levetiracetam
(N = 64) or placebo (N = 34) for 12 weeks. The CBCL
separates scores into a total problems score and a total
competence score. Among the per-protocol population
(levetiracetam, N = 46; placebo, N = 27), there was no
difference between treatment groups in the total com-
petence score but a significant difference in the total
problems score (P = 0.020) between levetiracetam
(worsening) and placebo (improvement). In the prob-
lems component of the CBCL, there was a significant
worsening of aggression with levetiracetam versus
placebo (P = 0.013), which drove the overall difference
in the problems score. In the competence component
of the CBCL, there was a small improvement with
levetiracetam versus placebo in the activities subscale
(P = 0.049). The Child Health Questionnaire–Parent
Form 50 score showed little change during treatment
and no significant between-group differences. A long-
term extension that included 80 patients who contin-
ued from this study and 23 additional patients found
no significant change from the baseline CBCL score
(or aggression subscale scores) with levetiracetam
(Schiemann-Delgado et al., 2012). From AE reporting
in this study, aggression was seen in 7.8% of patients,
irritability in 7.8%, and abnormal behavior in 3.9%.
One other study with levetiracetam specifically stud-
ied aggressive behavior but did not use standardized
measures. In 12 children with epilepsy with continuous
spikes and waves during slow sleep and pervasive
developmental disorder, parents reported the frequency
of seizures and frequency of episodes of panic or
aggressive behavior. In the eight patients whose sei-
zures improved with the addition of levetiracetam to
existing AEDs, six patients also had a $50% reduction
in the frequency of episodes of panic or aggression; there
was no change in episode frequency in the other two
responders (Kanemura et al., 2014).
There have been many RCTs and observational
studies with levetiracetam in children and adolescents;
rather than review them all here, the results of a recent
systematic review and meta-analysis of the behavioral
effects of levetiracetam are presented (Halma et al.,
2014). These authors included studies in children aged
from 1 month to 18 years with a diagnosis of epilepsy,
who were taking oral levetiracetam as monotherapy or
add-on therapy, with follow-up of at least 2 weeks and
which reported behavioral side effects. They excluded
case studies or case series with fewer than 10 patients,
studies of neonatal convulsions, and studies that in-
cluded adults and did not have separate subgroup
analyses for patients aged ,18 years. Their review
identified 13 studies in 727 patients. In the three RCTs
they identified, the most frequent behavioral AEs with
add-on levetiracetam (N = 165) were hostility (7.3%),
nervousness (6.1%), and aggression (4.9%). A meta-
analysis of these studies revealed a statistically significant
increased risk of behavioral AEs with levetiracetam
(risk ratio 2.18 versus placebo; 95% confidence interval,
1.42 to 3.37). Ten observational studies met their
selection criteria and these reported both worsening
and improvement of behavior with levetiracetam.
Levetiracetam add-on therapy was associated with
behavioral AEs of irritability (4.7%), hyperexcitabil-
ity (4.4%), and aggression (2.7%); monotherapy was
associated with behavioral problems in general (19%)
and irritability (2.6%). No meta-analysis was possible
across the observational studies.
Our searches identified the majority of the studies
included byHalma et al. (2014) in their systematic review
and meta-analysis, as well as a number of additional
studies that were excluded by their selection criteria.
Details of all of these studies can be found in Supplemen-
tal Table 2; the rates of behavioral AEs they report are
broadly in linewith those reported byHalma et al. (2014).
Mbizvo et al. (2014) performed another meta-analysis
of levetiracetam studies, which was also discussed
earlier (section V.B.11). This meta-analysis only in-
cluded two RCTs in children/adolescents, whereas
Halma et al. (2014) included three; when all of the
captured behavioral AE terms were combined across
these two studies for the child/adolescent populations,
an incidence of 40.6% (versus 21.4% with placebo) was
found. This seems remarkably high, especially consid-
ering the fact that the analysis excluded behavioral AEs
that were not reported in the original publications
because they were below the reporting thresholds
($5% or $10%); however, it is broadly consistent with
the doubling of risk (i.e., a risk ratio of approximately 2
versus placebo) as reported by Halma et al. (2014). The
terms included by Mbizvo et al. (2014) were hostility,
personality disorder, nervousness, depression, aggres-
sion, agitation, emotional lability, psychomotor hyper-
activity, irritability, abnormal behavior, altered mood,
anxiety, and dissociation. It was not clear, from their
article, whether they excluded “double counting” (e.g.,
adding together reports of AEs of aggression and
agitation when these occurred in the same subject); if
they did not exclude double counting, this could explain
the very large percentages of behavioral AEs in both the
levetiracetam and placebo groups.
11. Oxcarbazepine. Very little evidence of any
aggression-related features was found for oxcarbazepine,
and just one open-label study was identified (Supple-
mental Table 2). Northam et al. (2005) carried out a
prospective, open-label study of 24 young patients (aged
2–45 months). Oxcarbazepine was associated with
irritability in 5 of 24 patients (21%) in the treatment
phase (up to 30 days) and in 7 of 20 (35%) in the 6-month
extension phase (Northam et al., 2005). Oxcarbazepine
was discontinued in one of the patients with irritability
(who also had fatigue and ataxia). The usual comments
about the reliability of findings from small, open,
uncontrolled studies apply.
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12. Perampanel. Our searches identified one study
with perampanel in adolescents that used standardized
measures to assess behavior, one pooled analysis of
phase III clinical trials, and several observational
studies (Supplemental Table 2). Lagae et al. (2014)
reported a phase II, randomized, placebo-controlled
trial of add-on perampanel in 133 adolescents with
refractory focal-onset epilepsy; behavior was assessed
with the CBCL. There was no significant difference
between perampanel and placebo in the change from
baseline in CBCL total problem or total competence
scores, or in any of the subscales (e.g., aggression). AEs
related tohostility or aggression occurred in 17.6% (n=15)
of the perampanel-treated subjects (aggression, n = 7;
irritability, n = 6; anger, n =2; and laceration, n = 1) and
4.2% (n = 2) of the placebo group (aggression, n = 1;
irritability, n = 1).
Rosenfeld et al. (2015) reported pooled AE data for the
143 adolescents in the three phase III trials of peram-
panel. The most common AEs included aggression in
8.2% of adolescents versus 0% for placebo; this wasmore
frequent than in the overall perampanel-treated pop-
ulation (1.6%). Furthermore, aggression was reported
as being one of the most common reasons (6.6%) for
interruption or dose adjustment of the perampanel
among adolescents during the extension phase (Rosenfeld
et al., 2015).
The other perampanel reports come from observa-
tional studies. Biró et al. (2015) published a retrospec-
tive analysis of 58 children (mean age 10.3 years; range,
2–17 years) treated with perampanel. Aggression was
reported in eight patients (13.8%). In a retrospective
study of 18 patients (age range, 4–19 years), Philip et al.
(2014) reported behavioral change in only 1 patient (5.6%).
13. Phenobarbital. Four studies were identified for
phenobarbital (Supplemental Table 2). Willis et al.
(1997) carried out a neuropsychological and EEG study
of 11 children with epilepsy aged 7–14 years treated
with phenobarbital and mephobarbital. They stated
that parents reported clear behavioral changes in 6 of
11 subjects, including irritability, oppositional attitude,
and overactivity. In four of the six patients, the changes
were relatively mild and the barbiturate was not
discontinued.
In a large observational study that used parent
questionnaires, Domizio et al. (1993) compared 197
children (116 male and 81 female, mean age 5.3 years)
treated with phenobarbital, with 103 children (66 male
and 37 female, mean age 6.4 years) who were treated
with other AEDs. In the phenobarbital group, 150 chil-
dren (76.1%) had one or more behavioral disturbances,
compared with 32 (31%) in the other group (P, 0.0001).
Hyperactivity was themost frequent behavioral disorder
(Domizio et al., 1993).
In a randomized study of four AEDs (phenobarbital,
phenytoin, carbamazepine, and sodium valproate), de
Silva et al. (1996) discontinued the phenobarbital arm
after 6 of the first 10 children taking this drug had
unacceptable AEs, which were primarily behavioral. In
contrast, Pal et al. (1998) found no behavioral effects of
phenobarbital (N = 47) in a study in 94 children in India.
14. Phenytoin. Although anecdotally phenytoin is
associated with behavioral disturbance in young people,
no firm published evidence for this was found (Supple-
mental Table 2). In the study in India referred to above,
Pal et al. (1998) also found no behavioral effects of
phenytoin in 47 children. Krishnamoorthy et al. (1983)
reported three cases of phenytoin-induced choreoathe-
tosis associated with agitation/restlessness in three
young children: two were aged 2 years and one was aged
15 months.
15. Pregabalin. No evidence was found.
16. Primidone. Despite the fact that primidone is
partly metabolized to phenobarbital, no evidence of
aggression in children and teenagers with primidone
was found.
17. Retigabine. We identified only one study. Groen-
ing et al. (2012) treated 17 patients (aged from 1 year
and 10 months to 19 years) with retigabine for pharma-
coresistant seizures (Supplemental Table 2). Results
were analyzed for 12 patients, and AEs included
hallucinations, agitation, and personality changes. Fur-
ther details were not provided in this conference abstract
(Groening et al., 2012).
18. Rufinamide. In a recent consensus paper on
rufinamide in childhood epilepsy by Coppola et al.
(2014), aggression and related behaviors were not
reported among the adverse effects. There have been
few other reports of behavioral adverse effects with
rufinamide (Supplemental Table 2).
In a multicenter, prospective, add-on, observational
study of rufinamide in 43 children, adolescents, and
adults with Lennox–Gastaut syndrome (26 male and
17 female, aged 4–34 years, mean 15.9 years), Coppola
et al. (2010) reported irritability/aggressiveness in
3 patients (6.9%). In a separate observational study,
the effects of rufinamide in encephalopathies other than
Lennox–Gastaut syndromewere reported in 38 patients
(19 male and 19 female, aged 4–34 years, mean age
13.7 years). Irritability/aggressiveness was seen in two
patients (5.3%) (Coppola et al., 2011).
In a prospective, open-label, add-on trial in refractory
epilepsy in 69 children and adolescents, Cusmai et al.
(2014) reported irritability in 11 patients (15.9%). In a
retrospective study in 23 patients in Korea (age range,
4–22 years), Lee et al. (2013) reported aggressive
behavior in 2 patients (8.7%).
19. Stiripentol. One observational study was iden-
tified (Supplemental Table 2). Inoue et al. (2009)
reported clinical results using stiripentol to treat
Dravet syndrome in patients aged 1–22 years. Of 23
patients, 6 had hyperactivity/irritability early in treat-
ment, which resolved with continued treatment or dose
reduction. One patient (a 15-year-old girl) discontinued
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stiripentol because of early irritability (Inoue et al.,
2009).
20. Tiagabine. No evidence was found.
21. Topiramate. Two large retrospective studies,
together with several smaller studies and case studies,
were identified (Supplemental Table 2). Reith et al.
(2003) reported data in 159 patients with epilepsy aged
,18 years who were taking topiramate. Follow-up was
possible in 127 patients (0.5–17.9 years); aggression/
psychosis was a treatment-limiting AE in 10 of these
patients (7.9%) (Reith et al., 2003). Grosso et al. (2005)
treated 59 children aged #2 years with topiramate for
localization-related and generalized epilepsies. Irrita-
bility was listed as one of the most frequent AEs, but
precise rates were not given (Grosso et al., 2005). During
topiramate treatment, Lee et al. (2011a) reported that 4
of 28 infants (14.3%) aged 2–18 months with West
syndrome developed irritability, and Endoh et al. (2012)
reported that 5 of 33 children (15.2%) aged #12 years
with epileptic spasms developed irritability.
Metabolic acidosis is a known adverse effect of
topiramate, and this can be associated with irritability/
aggression (Ko and Kong, 2001). In patients taking
topiramate who present with hyperpnoea or mental
status change, metabolic acidosis must be excluded as a
possible cause.
22. Valproic Acid. Two studies were identified with
sodium valproate in adolescent epilepsy populations
(Supplemental Table 2). In a retrospective study of 100
children with epilepsy treated with sodium valproate,
Egger and Brett (1981) reported aggressive behavior in
4 (4%).
Ronen et al. (2000) studied eight children (six male
and two female, aged 6–12 years) without clinical
seizures but with abnormal EEGs and significant de-
velopmental learning disorder. While taking sodium
valproate, the children were more distractible, had
increased delay in response time, and had lowermemory
scores. Their parents also reported higher internalizing
scores on the CBCL while the children were taking
valproate (Ronen et al., 2000). In contrast, sodium
valproate and divalproex sodium are used extensively
as mood-leveling drugs in both adults and children in
nonepilepsy populations; for example, Hollander et al.
(2000) reported that impulsivity and aggression were
decreased in 14 patients with autism taking divalproex
sodium as a psychotropic medication.
23. Vigabatrin. We found no RCTs of vigabatrin
with behavior-specific endpoints, and we found one
observational study in children and adolescents that
focused on behavior (Supplemental Table 2). Sheth et al.
(1996) reported that in 31 patients aged 1–22 years
(meanage12.6 years)with refractory focal andgeneralized
seizures, add-on vigabatrin was associated with negative
behavior change in 6 children (based on parent reports),
with discontinuation in 1 patient with severe aggressive
agitation and positive behavior change in 1 patient.
The remaining studies we identified relied on AE
reporting from five observational studies, three case
reports, and six studies in babies with infantile spasms
(Supplemental Table 2). Gobbi et al. (1999) carried out a
prospective study of vigabatrin monotherapy in the
treatment of focal epilepsies in 40 children (mean age
at last visit 7.5 years) compared with 40 children
treated with carbamazepine monotherapy. They stated
that tolerability was good in the vigabatrin group but
4 of 37 patients had mild irritability at the end of the
trial (versus none in the carbamazepine-treated group).
Raucci et al. (1994) studied 61 children with various
types of epilepsy treated with vigabatrin, 12 as mono-
therapy and 49 as add-on therapy. Vigabatrin was
discontinued in six children because of adverse effects,
including irritability.
In the first of three case studies, Weber et al. (2012)
reported psychosis associated with vigabatrin in an
adolescent girl with refractory symptomatic epilepsy
after an earlymiddle cerebral artery insult. The onset of
the psychosis was 7 weeks after the vigabatrin was
commenced, when she had been seizure free for 2weeks.
They attributed this to the phenomenon of forced
normalization, although it should, more accurately, be
termed alternative psychosis or reciprocal psychosis
(the situation when the psychosis is likely to occur when
the seizure control has improved; see earlier). Two of the
teenage patients of one of the current authors also
developed psychosis with vigabatrin, which resolved
with dose reduction or discontinuation (F. Besag, per-
sonal communication). Cánovas Martínez et al. (1995)
published a case of a 7-year-old boy with refractory
epilepsy who developed an acute psychosis 3 days after
rapid introduction of vigabatrin. The psychosis resolved
within 48 hours of discontinuing the vigabatrin. Recom-
mencement of the vigabatrin 2 months later, using a
slower dose escalation, was well tolerated with no return
of the psychosis. Chiaretti et al. (1994) also published a
single case report of psychosis with vigabatrin in a child.
The data in infantile spasms are not presented here,
because AEs such as irritability in young infants cannot
be interpreted as aggression-related behaviors, but
studies are listed in Supplemental Table 2.
24. Zonisamide. We identified one studywith behavior-
specific outcomes and five additional studies reporting
behavioral AEs (Supplemental Table 2).
Eun et al. (2011) studied the neuropsychological and
behavioral effects of low-dose and high-dose zonisamide,
using a Korean version of the CBCL, in children aged
2–16 years receiving zonisamide monotherapy for
newly diagnosed epilepsy. Data were available for 63
patients (27 and 36 receiving low-dose and high-dose
treatment, respectively) and were presented as group
data, so it is not possible to determine whether some
patients became more aggressive and others less
aggressive. Overall, Eun et al. (2011) saw a signifi-
cant improvement (P , 0.05) in various parameters,
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including aggressive behavior, in the low-dose group
and a nonsignificant improvement in the high-dose
group. No aggression-related or behavior-related AEs
were reported.
Cross et al. (2014) carried out a pooled analysis of 17
zonisamide studies in patients aged 16 years or younger,
including 4 randomized, double-blind trials. Irritability
was reported in 5.8% of the 391 zonisamide-treated
patients but was not among the AEs commonly leading
to discontinuation. Irritability was somewhat more
common (7.5%) in patients aged 6–11 years than in
patients aged 12–16 years (,5%).
A phase III study by Guerrini et al. (2013) was
included in the meta-analysis by Cross et al. and is
thus not discussed in detail here. No aggression-related
AEs were reported in the zonisamide-treated group, but
one patient in the placebo group discontinued due to
aggression (Guerrini et al., 2013). In the subsequent
long-term extension study, there were no behavioral
AEs in patients continuing on zonisamide from the phase
III study but there were two cases of aggression (2.8%)
in patients who switched from placebo to zonisamide
during the extension (Guerrini et al., 2014).
Coppola et al. (2009) carried out a prospective, add-
on, open-label study of 82 young patients (45male and 37
female, aged 3–34 years, mean age 13.1 years). Irritabil-
ity was reported in nine patients (11.0%) but resolved in
most cases with dose reduction. No other behavioral
adverse effects were reported (Coppola et al., 2009).
Hirai et al. (2002) treated 27 children who had
idiopathic epilepsy with zonisamide in a prospective
study, observing behavioral disturbance in 2 children
(7.4%). One of the cases developed an obsessive-
compulsive disorder. The other case, a 14-year-old girl
with focal seizures whose seizures were treated effec-
tively with zonisamide from age 6 years, developed
selective mutism, violent behavior, and lack of concen-
tration at age 10 years. Decreasing the zonisamide dose
was said to have maintained adequate seizure control
while resolving the behavioral disturbance. Because of
the long time interval between the prescription of
zonisamide and the development of the violent behav-
ior, the direct role of the AED is questionable in this
case; amore likely explanationmight be that the violent
behavior was an interaction between seizure control
and developmental factors.
C. Conclusions
In most cases, there is inadequate evidence to draw
any firm conclusions about the aggression-related be-
havioral AEs associated with AEDs in children and
teenagers. From the evidence that is available, however,
it is suggested that children and adolescents who are
treated with gabapentin, levetiracetam, perampanel
(especially at higher doses), phenobarbital, sodium val-
proate, topiramate, and zonisamide should be monitored
closely for possible behavioral AEs. The most extensive
evidence is for levetiracetam but the reports of both
improvement and deteriorationwith this drug emphasize
the need for monitoring each individual patient for
positive or adverse effects of AEDs. Although there is
credible evidence for psychosis developing with viga-
batrin, this is more likely to be the phenomenon of
alternative or reciprocal psychosis that might have
occurred with any AED that achieved rapid seizure
control and could probably have been avoided by
starting at low doses and escalating the dose slowly.
This emphasizes the importance of excluding the
confounding factors that have been described in detail
elsewhere (Besag, 2001) before attributing behavioral
or aggression-related AEs to an AED.
VII. Avoidance and Management of Antiepileptic
Drug–Induced Aggression
Although there is a limited amount of good-quality
clinical data on aggression with AEDs in children,
adolescents, and adults with epilepsy, it is becoming
clear that there is increased propensity for some
patients to develop aggression-related behavior during
treatment with some AEDs. In a recent survey, for
example, 49% of 158 people with epilepsy treated with
levetiracetam reported aggression as sometimes or
always being a problem, whereas 39% of 260 patients
taking other AEDs were aware of anger issues and only
9% of 41 controls admitted to ever losing their temper
(Wieshmann and Baker, 2013). Based on the evidence
collected in this review (in sections V and VI), we can
conclude that 1) there is reasonable evidence of an
increased risk of aggressive behaviors occurring in
patients with epilepsy treated with levetiracetam,
perampanel, and topiramate and 2) that use of
gabapentin, phenobarbital, sodium valproate, and
zonisamide in children/adolescents also carries some risk.
What can we do to anticipate, identify, and ameliorate
aggressive-type behaviors that can occurwith these AEDs?
When it comes to anticipating which patients may
develop aggressive behaviors with AEDs, the evidence
is very limited. Previous psychiatric history is a pre-
dictive factor in some studies, but certainly not all
patients with a history of psychiatric illness or aggres-
sive behavior will go on to develop aggressive behavior
with higher-risk AEDs. However, when initiating treat-
ment with any AED, a personal and, if possible, a family
history of psychiatric disorders should be explored and
documented. All patients should be asked whether they
have a short temper, how often they lose it, and what is
the likely outcome. A similar question to accompanying
partners and family members often elicits a different
response, since some people are not aware that they
have this problem or appreciate its extent. Any history
of physical violence is of particular concern in this
context. If the patient has had serious anger manage-
ment issues in the past or has regularly demonstrated
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hostile or aggressive behavior, it does not necessarily
completely preclude using AEDs that have evidence for
increased risk of aggressive behaviors, but such AEDs
should be used with extreme caution or avoided alto-
gether based on clinical judgment. The decision will
involve weighing the risks of aggressive behaviors and
their possible effects against the risks of inadequate
seizure control and will be influenced by the other
treatment options available to the patient. Alcohol and
other stimulating agents can exacerbate aggression and
their effects should also be discussed with the patient,
partner, and family (Heinz et al., 2011). Providing
patients and/or carers with a medical contact number to
call if inappropriate behavior occurs is a sensible pre-
caution, particularly in patients who admit to frequently
losing their temper or to exhibiting aggressive behavior.
Regardless of the individual patient history, the potential
for aggressive behavior should be explained to the patient
and/or caregivers starting an AED associated with risk to
aid early detection of any problems. Finally, documenta-
tion of this discussion in the case notes and in the
correspondence with the patient’s general practitioner
should be considered as an integral part of good practice
and as an essential precaution. The possibility of later
medicolegal repercussions if a serious assault subse-
quently occurs underlines the importance of not only
following good practice but also documenting it.
In general, slow titration should be used when
possible, particularly when the patient is considered
at risk of aggressive behavior based on his or her
psychiatric history or selection of AED.
Certain groups of patients require special attention.
When introducing AEDs in teenagers, particularly
those with juvenile myoclonic epilepsy, clinicians must
be aware that some patients will have a tendency to
exhibit impulsive behavior (Crespel et al., 2013). Par-
ticular attention should also be paid to patients with
intellectual disability, who cannot easily express their
frustrations in an acceptable way, and those with
dementia, who may demonstrate unexpected violent
behavior (Newman, 2012). The possibility of release
phenomena in patients with intellectual disability
should also be considered (Besag, 2001). Some AEDs,
such as the sodium channel blockers carbamazepine,
oxcarbazepine, and, particularly, lamotrigine (Labiner
et al., 2009) or valproic acid, may be better choices in
these situations (Comai et al., 2012b).
Another possibility to help anticipate aggressive
responses is to use questionnaires to screen patients.
There are a number of published and validated scoring
systems for measuring aggression that could be used in
patients with epilepsy (Silver and Yudofsky, 1991; Buss
and Perry, 1992; Harris, 1995). An instrument for
measuring irritability in people with epilepsy was also
recently published (Piazzini et al., 2011).
If irritability, anger, hostility, or aggressive behaviors
do develop or worsen, managing these depends on their
severity and the extent of the positive pharmacological
response to the implicated AED. This consideration is
particularly important in patients with severe pharma-
coresistant epilepsy in whom other treatment options
may be limited. Dose reduction of the most recently
added AED should be considered. Reducing alcohol
intake can also be a helpful step in ameliorating aggres-
sion. Often, however, the aggressive behavior can only be
stopped by discontinuing the AED. The decision whether
to maintain AED treatment in this setting should be
made in discussion with the patient, partner, and family;
again, this discussion should be documented in the
patient’s case notes. If the AED is continued, improve-
ment in anger-related symptoms can occur with time,
although this appears to be relatively uncommon, and
anger management programs can also be a helpful
addition to the therapeutic regimen, particularly in
seizure-free patients. It is important to make the
patient’s general practitioner fully aware of the situa-
tion, stating which AED is implicated.
If the AED is continued, and/or the aggressive
behavior continues, then pharmacological management
of the behavior may be warranted. There is, however, no
single pharmacological strategy recommended for the
management of anger and aggression (Newman, 2012).
Antipsychotic, antidepressant, and other psychotropic
agents have all been used to ameliorate these behaviors
(Alper et al., 2002; Nevels et al., 2010), and there is also
evidence that mood stabilizers (e.g., carbamazepine,
oxcarbazepine, phenytoin, and lithium) are significantly
better than placebo in reducing aggressive behavior
(Jones et al., 2011). Pharmacological management of
aggression can be complicated by proseizure effects of
some psychotropic medications, particularly in higher
doses (Varma et al., 2011). Existing treatment of
psychiatric comorbidities, particularly depression, anxiety,
psychosis, panic attacks, bipolar symptoms, and attention
deficit disorder, should be reviewed.
If the comorbid psychiatric symptoms are chronic and
severe, it is advisable that the patient also remains
under the care of an experienced psychiatrist. Manag-
ing psychiatric comorbidities is not always an attractive
option for the neurologist, but this should be attempted
if prompt management from a psychiatrist is not avail-
able and the symptoms are relativelymild and amenable
to standard pharmacological intervention with widely
used mood-stabilizing drugs.
VIII. Overall Summary
One of the major areas of interest in the management
of epilepsy is the effect of psychiatric comorbidities on
the choice of and response to AED therapy (Hitiris et al.,
2007). There is, of course, substantial overlap among
their clinical presentations in the setting of newly
diagnosed and refractory epilepsy (Lin et al., 2012).
There has been particular concern recently regarding
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the potential for some of these drugs to cause or worsen
hostility and aggression, with possible medicolegal
consequences. This evidence-based review discusses
for the first time the relationship between epilepsy,
AEDs, and aggression, covering a wide range of issues
including definitions, psychiatric comorbidities and
epilepsy, the neurobiology and pharmacology of aggres-
sion, and evidence for each AED in causing or exacer-
bating this problem in children, adolescents, and adults,
and some suggestions for prevention and management
are also provided. The main conclusion must be that
better quality evidence and comparative studies are
needed to clarify the link between AEDs and aggressive
behavior in patients with epilepsy. However, based on
the available evidence, some AEDs seem to be associ-
ated with higher risk than others, including clobazam,
clonazepam, levetiracetam, perampanel, phenobarbi-
tal, tiagabine, topiramate, vigabatrin, and zonisamide
(in alphabetical order). The potential for aggressive
behavior should be explained to every patient starting
treatment with any of these drugs, particularly patients
with known anger management issues. The AEDs with
strongest evidence for a risk of aggressive behaviors are
levetiracetam, perampanel, and possibly topiramate,
but the majority of patients taking these, and any other
AEDs, will have no problems with aggressive behaviors.
Involvement of partners and families is important,
since many people are not aware that they have a short
temper or that their demeanor could be perceived as
aggressive. These issues should be taken into consider-
ation when making the choice of AED therapy for all
patients with newly diagnosed and chronic epilepsy.
Future research should clarify the neurobiology of
aggression and epilepsy and may help clinical decision
making and treatment selection to avoid problems with
aggression in patients with epilepsy.
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